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A B S T R A C T
Background
Venous thromboembolism (VTE) is a collective term for two conditions: deep vein thrombosis (DVT) and pulmonary embolism
(PE). A proportion of people with VTE have no underlying or immediately predisposing risk factors and the VTE is referred to as
unprovoked. Unprovoked VTE can often be the ﬁrst clinical manifestation of an underlying malignancy. This has raised the question
of whether people with an unprovoked VTE should be investigated for an underlying cancer. Treatment for VTE is different in cancer
and non-cancer patients and a correct diagnosis would ensure that people received the optimal treatment for VTE to prevent recurrence
and further morbidity. Furthermore, an appropriate cancer diagnosis at an earlier stage could avoid the risk of cancer progression and
lead to improvements in cancer-related mortality and morbidity. This is an update of a review ﬁrst published in 2015.
Objectives
To determine whether testing for undiagnosed cancer in people with a ﬁrst episode of unprovoked VTE (DVT of the lower limb or PE)
is effective in reducing cancer or VTE-related mortality and morbidity and to determine which tests for cancer are best at identifying
treatable cancers early.
Search methods
The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase
and CINAHL databases and World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov trials
registers to 11 July 2018. We also undertook reference checking to identify additional studies.
Selection criteria
Randomised and quasi-randomised trials in which people with an unprovoked VTEwere allocated to receive speciﬁc tests for identifying
cancer or clinically indicated tests only were eligible for inclusion. Primary outcomes included all-cause mortality, cancer-related
mortality and VTE-related mortality.
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Data collection and analysis
Two review authors independently selected studies, assessed risk of bias and extracted data.We resolved any disagreements by discussion.
Main results
No new studies were identiﬁed for this 2018 update. In total, four studies with 1644 participants are included. Two studies assessed the
effect of extensive tests including computed tomography (CT) scanning versus tests at the physician’s discretion, while the other two
studies assessed the effect of standard testing plus positron emission tomography (PET)/CT scanning versus standard testing alone. For
extensive tests including CT versus tests at the physician’s discretion, the quality of the evidence, as assessed according to GRADE, was
low due to risk of bias (early termination of the studies). When comparing standard testing plus PET/CT scanning versus standard
testing alone, the quality of evidence was moderate due to a risk of detection bias. The quality of the evidence was downgraded further
as detection bias was present in one study with a low number of events.
When comparing extensive tests including CT versus tests at the physician’s discretion, pooled analysis on two studies showed that
testing for cancer was consistent with either beneﬁt or no beneﬁt on cancer-related mortality (odds ratio (OR) 0.49, 95% conﬁdence
interval (CI) 0.15 to 1.67; 396 participants; 2 studies; P = 0.26; low-quality evidence). One study (201 participants) showed that,
overall, malignancies were less advanced at diagnosis in extensively tested participants than in participants in the control group. In
total, 9/13 participants diagnosed with cancer in the extensively tested group had a T1 or T2 stage malignancy compared to 2/10
participants diagnosed with cancer in the control group (OR 5.00, 95% CI 1.05 to 23.76; P = 0.04; low-quality evidence). There was
no clear difference in detection of advanced stages between extensive tests versus tests at the physician’s discretion: one participant in
the extensively tested group had stage T3 compared with four participants in the control group (OR 0.25, 95% CI 0.03 to 2.28; P =
0.22; low-quality evidence). In addition, extensively tested participants were diagnosed earlier than control group (mean: 1 month with
extensive tests versus 11.6 months with tests at physician’s discretion to cancer diagnosis from the time of diagnosis of VTE). Extensive
testing did not increase the frequency of an underlying cancer diagnosis (OR 1.32, 95% CI 0.59 to 2.93; 396 participants; 2 studies;
P = 0.50; low-quality evidence). Neither study measured all-cause mortality, VTE-related morbidity and mortality, complications of
anticoagulation, adverse effects of cancer tests, participant satisfaction or quality of life.
When comparing standard testing plus PET/CT screening versus standard testing alone, standard testing plus PET/CT screening was
consistent with either beneﬁt or no beneﬁt on all-cause mortality (OR 1.22, 95% CI 0.49 to 3.04; 1248 participants; 2 studies; P =
0.66; moderate-quality evidence), cancer-related mortality (OR 0.55, 95% CI 0.20 to 1.52; 1248 participants; 2 studies; P = 0.25;
moderate-quality evidence) or VTE-related morbidity (OR 1.02, 95% CI 0.48 to 2.17; 854 participants; 1 study; P = 0.96; moderate-
quality evidence). Regarding stage of cancer, there was no clear difference for detection of early (OR 1.78, 95% 0.51 to 6.17; 394
participants; 1 study; P = 0.37; low-quality evidence) or advanced (OR 1.00, 95% CI 0.14 to 7.17; 394 participants; 1 study; P = 1.00;
low-quality evidence) stages of cancer. There was also no clear difference in the frequency of an underlying cancer diagnosis (OR 1.71,
95% CI 0.91 to 3.20; 1248 participants; 2 studies; P = 0.09; moderate-quality evidence). Time to cancer diagnosis was 4.2 months
in the standard testing group and 4.0 months in the standard testing plus PET/CT group (P = 0.88). Neither study measured VTE-
related mortality, complications of anticoagulation, adverse effects of cancer tests, participant satisfaction or quality of life.
Authors’ conclusions
Speciﬁc testing for cancer in people with unprovoked VTE may lead to earlier diagnosis of cancer at an earlier stage of the disease.
However, there is currently insufﬁcient evidence to draw deﬁnitive conclusions concerning the effectiveness of testing for undiagnosed
cancer in people with a ﬁrst episode of unprovoked VTE (DVT or PE) in reducing cancer- or VTE-relatedmorbidity and mortality. The
results could be consistent with either beneﬁt or no beneﬁt. Further good-quality large-scale randomised controlled trials are required
before ﬁrm conclusions can be made.
P L A I N L A N G U A G E S U M M A R Y
Effect of testing for cancer (on cancer and blood clot-related death and illness) in people with unprovoked blood clots in the
legs and lungs
Background
Venous thromboembolism (VTE) refers to blood clots in leg veins (known as deep venous thrombosis (DVT)), which can travel to
the lungs (causing pulmonary embolism (PE)). PE can often be fatal. Signs of DVT include pain and swelling of the leg while signs of
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PE include breathlessness and chest pain. Risk factors for VTE include surgery, prolonged bed rest, trauma, family history, pregnancy
and blood deﬁciencies. Sometimes a VTE happens for no apparent reason (it is unprovoked). In such people, an undetected cancer
may be the cause of the VTE. This has raised the question of whether people with an unprovoked VTE should be investigated for
underlying cancer. This is important as the management of VTE in people with and without cancer differs. A cancer diagnosis would
ensure people receive the optimal treatment to reduce the risk of another VTE. A diagnosis could also lead to the cancer being treated
earlier, at a more curable stage.
Study characteristics and key results
This review assessed whether testing for undiagnosed cancer in people with a ﬁrst unprovoked VTE (DVT or PE) was effective in
reducing cancer and VTE-related illness and death. We found four studies with 1644 participants (current to July 2018). Two studies
compared extensive cancer tests with tests carried out at the physician’s discretion and two studies compared cancer tests plus scanning
with cancer tests alone. Combining the results of the two studies showed that extensive testing had no effect on the number of cancer-
related deaths. Additionally, extensive testing did not identify more people with cancer. However, extensive testing did identify cancers
at an earlier stage (approximately 10 months earlier) and cancers were less advanced in people in the extensive testing group than in
people in the group with tests carried out at the physician’s discretion. Neither study looked at the number of deaths due to any cause,
deaths and illness associated with VTE, side effects of cancer tests, side effects of VTE treatment or participant satisfaction. Two studies
that compared tests plus scanning with tests alone showed that adding computed tomography scanning had little or no effect on the
number of deaths, cancer-related deaths, illness associated with VTE; nor did it identify more people with cancer, or show a clear
difference in time to diagnosis or stages of cancer diagnosed. Neither study looked at deaths associated with VTE, side effects of cancer
tests, side effects of VTE treatment, participant satisfaction or quality of life.
Quality of the evidence
When comparing extensive tests versus tests at the physician’s discretion, the quality of the evidence was low due to bias caused by two
of the studies stopping early. When comparing tests plus PET/CT scanning with tests alone, the quality of the evidence ranged from
low to moderate due to imprecision caused by a low number of events and bias due to lack of blinding of people assessing the effects.
This review found that there are too few trials to determine whether testing for undiagnosed cancer in people with a ﬁrst unprovoked
VTE (DVT or PE) is effective in reducing cancer and VTE-related deaths and illness. Further good-quality and large-scale studies are
required.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Extensive tests versus tests at the physician’s discretion
Patient or population: people with unprovoked VTE
Setting: hospital
Intervention: extensive tests
Comparison: tests at the physician’s discret ion
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with tests at
physician’s discretion
Risk with extensive
tests
All- cause mortality 1 See comment See comment See comment See comment See comment No study measured this
outcome.
Cancer- related mortal-
ity 2
Study populat ion OR 0.49
(0.15 to 1.67)
396
(2 RCTs)
⊕⊕©©
Low 3
-
40 per 1000 20 per 1000
(6 to 65)
VTE- related mortality 4 See comment See comment See comment See comment See comment No study measured this
outcome.
VTE- related morbidity
5
See comment See comment See comment See comment See comment No study measured this
outcome.
Stage of cancer - early
6
Study populat ion OR 5.00
(1.05 to 23.76)
201
(1 RCT)
⊕⊕©©
Low 7
-
20 per 1000 91 per 1000
(21 to 322)
Stage of cancer - ad-
vanced 8
Study populat ion OR 0.25
(0.03 to 2.28)
201
(1 RCT)
⊕⊕©©
Low 7
-
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39 per 1000 10 per 1000
(1 to 85)
Time to cancer diagno-
sis 9
See comments See comments See comments 201
(1 RCT)
See comments Time to cancer diag-
nosis (measured f rom
time of diagnosis of
VTE) measured in 1
study (Piccioli 2004b)
, and reported as a
mean of 1 month with
extensive tests com-
pared to 11.6 months
with tests at physician’s
discret ion (P < 0.001)
. Standard deviat ions
for these means not
given. Attempts to con-
tact author for these
data made but no re-
sponse received
Frequency of underly-
ing cancer diagnosis 10
60 per 1000 78 per 1000
(36 to 158)
OR 1.32
(0.59 to 2.93)
396
(2 RCTs)
⊕⊕©©
Low 3
-
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; OR: odds rat io; RCT: randomised controlled trial; VTE: venous thromboembolism.
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Death due to any cause.
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2 Def ined as death due to malignant disease itself , or death due to complicat ions of treatments or procedures to diagnose or
treat cancer.
3 Risk of bias was high in two included studies (Piccioli 2004b; Prandoni 2016). Piccioli 2004b term inated early af ter inclusion
of only 201 part icipants af ter 5 years for several reasons. First , only f ive of more than 40 potent ial part icipat ing centres
could contribute part icipants to study. Second, some medical ethics committees rejected the protocol because of absence of
screening for occult cancer in the control group, other centres could not start because the proposed extensive screening was
judged unethical. Finally, ident if icat ion of cancer at an apparent early stage in extensive screening group led to an increasing
tendency among physicians in part icipat ing hospitals to init iate screening for cancer in control part icipants. Prandoni 2016
study term inated early due to low recruitment rate and failure to show an appreciable advantage of CT-based strategy over
control strategy for detect ion of cancer.
4 Fatal pulmonary embolism (PE). PE diagnosed ‘‘on the basis of a lung scan indicat ing a high probability of its presence,
as indicated by the presence of new or enlarged areas of segmental perfusion defects with vent ilat ion-perfusion mismatch;
an abnormal perfusion scan with documentat ion of new or recurrent deep vein thrombosis (DVT); the presence of non-
enhancing f ill ing defects in the central pulmonary vasculature on helical computed tomography; a f inding of intraluminal
f il l ing defects on pulmonary angiography; or evidence of f resh PE at autopsy’’ (Lee 2003b). Fatal PE including probable fatal
PE and unexplained sudden death used if reported, as def ined by individual studies.
5 Frequency of recurrent VTE. Recurrent PE or DVT diagnosed if a previously compressible proximal venous segment or
segments could no longer be compressed on ultrasonography or if there were constant intraluminal f il l ing defects in two
or more project ions on venography. Unequivocal extension of the thrombus required for diagnosis of recurrence if results
abnormal on previous test ing (Lee 2003b)
6 Early-stage malignancies, def ined as T1 or T2 without locoregional or distant metastases (N0 M0).
7 Quality of evidence downgraded for imprecision due to low number of events. Evidence downgraded further as risk of bias
high in Piccioli 2004b. Study term inated early af ter inclusion of only 201 part icipants af ter f ive years for several reasons. First ,
only f ive of more than 40 potent ial part icipat ing centres could contribute part icipants to study. Second, some medical ethics
committees rejected the protocol because of absence of screening for occult cancer in the control group, other centres could
not start because the proposed extensive screening was judged unethical. Finally, ident if icat ion of cancer at an apparent
early stage in extensive screening group led to an increasing tendency among physicians in part icipat ing hospitals to init iate
screening for cancer in control part icipants.
8 Advanced-stage malignancies, def ined as T3 with locoregional or distant metastases (N1 or M1).
9 Time to cancer diagnosis, as def ined in included studies.
10 Frequency of an underlying cancer diagnosis (i.e. number of t imes cancer diagnosed through screening following an
unprovoked VTE as def ined in included studies) at t ime of VTE presentat ion and overall over follow-up period.
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B A C K G R O U N D
Description of the condition
Venous thromboembolism (VTE) is the collective term for the
clinical conditions deep vein thrombosis (DVT) and pulmonary
embolism (PE). DVT is the formation of a blood clot (thrombus)
in a deep vein, predominantly in the legs. Symptoms include pain,
tenderness, erythema and swelling of the affected leg. PE occurs
when part or all the thrombus breaks off (embolises) and travels
up to the lungs blocking the pulmonary arteries. Symptoms of PE
include breathlessness and chest pain (Blann 2006).
Guidelines published by the UKNational Institute for Health and
Care Excellence (NICE) recommend that people with a suspected
VTE should be risk stratiﬁed using various diagnostic investiga-
tions. Anticoagulant therapy with low molecular weight heparin
(LMWH) should be administered in the interim. People with con-
ﬁrmed VTE should receive LMWH or fondaparinux for at least
the initial ﬁve days and be started on a vitamin K antagonist. The
LMWH should be stopped when the international normalised ra-
tio has been above 2 for at least 24 hours. Vitamin K antagonists
should be continued for at least three months. In people with an
unprovoked VTE, consideration should be given to extending an-
ticoagulation beyond threemonths. However, people with cancer-
associated VTE should be treated with LMWH from the initial
diagnosis for a period of six months, and considered for continua-
tion of anticoagulation with either LMWH or a vitamin K antag-
onist based on the status of the underlying cancer and risks of an-
ticoagulation (NICE 2012). Direct oral anticoagulants (DOACs)
such as rivaroxaban have been used for the initial treatment and
prevention of recurrent VTE. Two systematic reviews have shown
that DOACs may be as safe and effective as conventional anti-
coagulation for the prevention of recurrent VTE in people with
cancer but, direct comparisons to the current standard of care with
LMWH are limited (Carrier 2014; Vedovati 2015).
The difference in management of people with a cancer-associated
VTE is due to their signiﬁcantly higher risk of VTE recurrence,
which is estimated to be three times higher than in people with
VTE in the absence of cancer (Levitan 1999). Furthermore, people
with cancer and an associated VTE have a poorer overall prognosis
compared to people without a VTE (Sorensen 2000).
A proportion of people with VTE have no underlying or immedi-
ately apparent cause and theVTE is referred to as unprovoked.Un-
provoked VTE can suggest underlying malignancies such as can-
cer of the blood, kidney, ovary, pancreas, stomach and lung (Bick
1978; Kakkar 2003; Lee 2003a; Prandoni 1997;White 2005). Re-
sults from one Swedish prospective cohort study of almost 62,000
participants determined that the standardised incidence ratio of a
cancer diagnosis within the ﬁrst two years of an unprovoked VTE
was 4.4 (Baron 1998), and there was an overall absolute incidence
of cancer of 11% (NICE 2012). One study of 339 participants
with a ﬁrst episode of an unprovoked VTE determined that the
risk ratio (RR) of cancer-related mortality at two years was 0.52
(95% conﬁdence interval (CI) 0.10 to 2.75) in people undergoing
intensive investigations compared to routine tests, while the RR
for early-stage cancer detection was 3.21 (95% CI 0.88 to 11.79)
(Piccioli 2004a).
Therefore, people who present with an apparent unprovoked VTE
have a signiﬁcant underlying risk of malignancy or cancer-associ-
atedVTE, with signiﬁcant implications for themanagement of the
VTE itself (three months’ vitamin K antagonist versus six months’
LMWH), the prognosis related to risk of VTE recurrence and the
precipitating cancer. Detection of cancer at an earlier stage enables
more effective treatment. This has raised the question of whether
people with an unprovoked VTE should be investigated for an
underlying cancer. Some authors have referred to this as ’screen-
ing for cancer’ although this is somewhat misleading as screening
refers to the investigation of asymptomatic people. Instead, peo-
ple with VTE are better regarded as presenting with symptoms
suggestive of an underlying cancer and the aim of investigations is
to reﬁne the diagnosis of VTE based on the underlying cause, so
that the person may receive a more accurate diagnosis and appro-
priate treatment for their VTE. In this context, VTE represents a
symptom rather than a diagnosis per se. So, to what extent should
people with an unprovoked VTE be investigated for a potential
underlying cancer?
NICE guidelines recommend that all people presenting with a ﬁrst
episode of unprovoked VTE (DVT or PE) should undergo a his-
tory and physical examination directed to detecting an underlying
malignancy, and further tests guided by the history and examina-
tion including blood tests (complete blood count, serum calcium
and liver function tests), urinalysis and chest X-ray (NICE 2012).
If none of these initial investigations suggest signs and symptoms
of cancer then further tests including abdomino-pelvic computed
tomography (CT) scan and positron emission tomography (PET)
scans and ultrasound, are recommended. It is the value of these
additional tests which is the subject of this review.
Description of the intervention
A number of imaging techniques are used in the detection of
cancers including computed tomography (CT), positron emission
tomography (PET) and ultrasound (US).
CT scans use x-rays to produce cross-sectional, three-dimensional,
images of structural changes due to malignancy. An intravenous,
iodine agent is used to increase the contrast between the tumour
and normal tissue. CT provides a very high spatial resolution but
is limited in its ability to accurately distinguish between benign
and malignant tissue on the basis of structural information alone,
and image interpretation can be difﬁcult where normal anatomy
is distorted (Chin 2008).
A PET scan uses low-dose radiation to measure the activity of
cells, producing images that represent the functional rather than
anatomical characteristics of disease. 18F-ﬂuoro-2-deoxy-D-glu-
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cose (FDG) is used as a contrast agent as it is taken up strongly by
many aggressive malignant tumours, but weakly by any normal
physiological structures of the human body, resulting in an ex-
cellent lesion-to-background contrast (Buthiau 2003). FDG-PET
imaging alone is limited by a lack of anatomical data so it is com-
bined with CT in a single machine that performs both imaging
techniques. Integrated PET/CT images combining the anatomical
data of CT with the functional data of PET imaging, can detect
lesions smaller than 1 cm which other imaging techniques cannot
clearly classify as benign or malignant (Buthiau 2003; Chen 2004;
Schöder 2007).
Ultrasound scanning uses high frequency sound waves to build
up a picture of internal organs. The sound waves echo differently
when bounced off healthy and abnormal tissue. While US can
distinguish ﬂuid-ﬁlled cysts from solid tumours, it cannot tell if
a tumour is malignant. The images are not as detailed as CT or
MRI scan images and it is limited to speciﬁc parts of the body as
the waves cannot travel through air (the lungs) or bone. US is one
of the most common imaging methods used in the diagnosis of
tumours in the thyroid, breast, prostate, liver, pancreatic, ovarian,
uterine and kidney (Fass 2008).
How the intervention might work
The interventions for detecting an underlying cancer will enable
a diagnosis of cancer-associated VTE to be made. This will enable
the person to receive appropriate anticoagulation with LMWH
versus vitamin K antagonist, for six versus three months respec-
tively, and for the underlying cancer to be treated promptly with-
out the need for additional symptoms to emerge before it is diag-
nosed. One study has shown that the combination of tests recom-
mended by NICE detects cancer in approximately 10% of people
with a ﬁrst episode of unprovoked VTE and with no prior cancer
diagnosis (Piccioli 2004a). However, tests for cancer also have the
potential for harm, from the pain and inconvenience of blood tests
to more serious complications due to radiation exposure from X-
rays and CT scans.
Why it is important to do this review
The pharmacological management of VTE in people with and
without cancer is considerably different, both in terms of choice of
agent and duration of anticoagulation. Therefore, an appropriate
cancer diagnosis would ensure that people received the optimal
form and duration of anticoagulation, which, in turn, could re-
duce the overall population VTE recurrence rate and associated
morbidity. Establishing whether a person with an apparently un-
provoked VTE has an underlying cancer is important since this
may lead to cancer diagnosis at an earlier, potentially curative stage,
avoiding the risk of cancer progression while waiting for additional
symptoms. This may, in turn, lead to improvements in cancer-
related mortality and morbidity. To date, no systematic review has
been conducted to measure the effectiveness of testing for cancer
in people with an unprovoked VTE. This review provides evi-
dence as to whether such tests for underlying cancer, followed by
appropriate alteration in the management or treatment of VTE,
or both, are effective in reducing morbidity (VTE recurrence) and
mortality (VTE- and cancer-associated).
O B J E C T I V E S
To determine whether testing for undiagnosed cancer in people
with a ﬁrst episode of unprovoked VTE (DVT of the lower limb
or PE) is effective in reducing cancer and VTE-related mortality
and morbidity and to determine which tests for cancer are best at
identifying treatable cancers early.
The detailed objectives are as follows:
to determine whether testing for undiagnosed cancer in people
with a ﬁrst episode of unprovoked VTE (DVT of the lower limb
or PE) is effective in reducing cancer mortality and morbidity
(cancer morbidity being the need for cancer treatment and effects
producing reduced quality of life);
to determine whether testing for undiagnosed cancer in people
with a ﬁrst episode of unprovoked VTE (DVT or PE) is effective
in reducing VTE-related mortality and morbidity;
to determine which tests for cancer are best at identifying treatable
cancers early.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised and quasi-randomised trials (where a method of al-
location was used that was not truly random) in which people
with an unprovoked VTE were allocated to receive different tests
for cancer or tests as per physician discretion. We looked primar-
ily at randomisation within three months of a VTE, as used in
the SOMIT trial (Piccioli 2004a). However, we also included tri-
als where randomisation occurred at different time points as a
subgroup analysis. We included published studies and studies in
progress if preliminary results were available. Non-English lan-
guage studies were also eligible for inclusion in the review.
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Types of participants
People with a ﬁrst episode of unprovoked VTE (DVT of the lower
limb or PE) with no pre-existing or clinically apparent cancer
diagnosis.
Types of interventions
Tests for cancer (e.g. complete blood count, serum calcium, liver
function test, urinalysis, chest X-ray, all forms of CT imaging,
mammogram, tumour markers, sputum cytology, ultrasonogra-
phy, positron emission tomography (PET) scan and colonoscopy)
versus no tests for cancer or alternative tests, followed by appro-
priate treatment for cancer or change in VTE treatment regimen,
or both. Studies where these tests were routinely used in all groups
were not included. However, we included any study that focused
on some other aspect of care than cancer only if the test for cancer
was the subject of randomisation.
Types of outcome measures
Primary outcomes
1. All-cause mortality (death due to any cause).
2. Cancer-related mortality (deﬁned as death due to a
malignant disease itself, or death due to complications of
treatments or procedures to diagnose or treat the cancer).
3. VTE-related mortality (fatal PE). PE diagnosed “on the
basis of a lung scan indicating a high probability of its presence,
as indicated by the presence of new or enlarged areas of
segmental perfusion defects with ventilation-perfusion
mismatch; an abnormal perfusion scan with documentation of
new or recurrent DVT; the presence of non-enhancing ﬁlling
defects in the central pulmonary vasculature on helical CT; a
ﬁnding of intraluminal ﬁlling defects on pulmonary
angiography; or evidence of fresh PE at autopsy” (Lee 2003b).
Fatal PE including probable fatal PE and unexplained sudden
death were used if reported, as deﬁned by individual studies.
Secondary outcomes
1. VTE-related morbidity (e.g. frequency of recurrent VTE).
Recurrent PE or DVT was diagnosed if a previously compressible
proximal venous segment or segments could no longer be
compressed on ultrasonography or if there were constant
intraluminal ﬁlling defects in two or more projections on
venography. Unequivocal extension of the thrombus required for
the diagnosis of recurrence if the results were abnormal on
previous testing (Lee 2003b).
2. Complications of anticoagulation (e.g. warfarin- versus
LMWH-associated bleeding). We reported on major bleeding
and minor bleeding if reported in the included studies. Major
bleeding included bleeding associated with death, bleeding at a
critical site (intracranial, intraspinal, intraocular, retroperitoneal
or pericardial area), bleeding resulting in a need for a transfusion
of at least two units of blood or bleeding leading to a drop in
haemoglobin of at least 2.0 g/dL (Lee 2003b). Minor bleeding
included any other bleeding.
3. Adverse effects of cancer tests (e.g. radiation exposure,
bleeding, as deﬁned in included studies).
4. Characteristics of diagnosed cancer (e.g. primary tumour,
stage, localised (curable) versus advanced (palliative) as deﬁned
in included studies).
5. Time to cancer diagnosis, as deﬁned in included studies.
6. Frequency of an underlying cancer diagnosis (i.e. the
number of times cancer was diagnosed through screening
following an unprovoked VTE as deﬁned in included studies) at
the time of VTE presentation and overall over the follow-up
period.
7. Participant satisfaction (if assessed in individual studies, we
reported results descriptively using the deﬁnition provided by the
trialists).
8. Quality of life.
Search methods for identification of studies
There were no restrictions on date or language of publication.
Electronic searches
The Cochrane Vascular Information Specialist conducted system-
atic searches of the following databases for randomised controlled
trials and quasi-randomised trials.
1. The Cochrane Vascular Specialised Register via the
Cochrane Register of Studies (CRS-Web searched on 11 July
2018).
2. The Cochrane Central Register of Controlled Trials
(CENTRAL) Cochrane Register of Studies Online (CRSO
2018, Issue 6).
3. MEDLINE (Ovid MEDLINE® Epub Ahead of Print, In-
Process & Other Non-Indexed Citations, Ovid MEDLINE®
Daily and Ovid MEDLINE®) (searched from 1 January 2017 to
11 July 2018).
4. Embase Ovid (searched from 1 January 2017 to 11 July
2018).
5. CINAHL Ebsco (searched from 1 January 2017 to 11 July
2018).
6. AMED Ovid (searched from 1 January 2017 to 11 July
2018).
The Information Specialist modelled search strategies for other
databases on the search strategy designed for CENTRAL. Where
appropriate, they were combined with adaptations of the highly
sensitive search strategy designed by the Cochrane Collaboration
for identifying randomised controlled trials and controlled clinical
trials (as described in theCochrane Handbook for Systematic Reviews
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of Interventions Chapter 6, Lefebvre 2011). Search strategies for
major databases are provided in Appendix 1.
The Information Specialist searched the following trials registries
on 11 July 2018:
1. The World Health Organization International Clinical
Trials Registry Platform (who.int/trialsearch);
2. ClinicalTrials.gov ( clinicaltrials.gov).
Searching other resources
We searched the reference lists of relevant articles retrieved by
the electronic searches for additional citations. Furthermore, we
searched the conference proceeding abstracts of the following so-
cieties:
1. International Society for Thrombosis and Haemostasis
(ISTH) (2003 to 2016);
2. American Society for Hematology (ASH) (2004 to 2016).
Data collection and analysis
Selection of studies
Two of three review authors (LR, SEY, CB) independently used
the selection criteria to identify trials for inclusion. We resolved
any disagreements by discussion.
Data extraction and management
Two review authors (LR, SEY) independently extracted the data
and recorded information about the trial design, VTE deﬁnition
and investigations to conﬁrm diagnosis, baseline characteristics
of participants and tests for cancer. All-cause mortality, cancer-
related mortality and VTE-related mortality data were recorded
as the primary outcome measures. Information on VTE-related
morbidity (e.g. frequency of recurrent VTE), complications of an-
ticoagulation (e.g. warfarin- versus LMWH-associated bleeding),
adverse effects of cancer tests (e.g. radiation exposure, bleeding),
characteristics of diagnosed cancer (e.g. primary tumour, stage, lo-
calised (curable) versus advanced (palliative)), time to cancer diag-
nosis, frequency of an underlying cancer diagnosis and participant
satisfaction was collected in accordance with the secondary out-
come measures. Where more than one publication of one study
existed, reports were grouped together and themost recent ormost
complete data set were used. We contacted authors of included
studies for further information if clariﬁcation was required. We
resolved any disagreements in data extraction and management by
discussion.
Assessment of risk of bias in included studies
Two review authors (LR, SEY) independently used the Cochrane
tool to assess the risk of bias for each of the included studies
(Higgins 2011). The tool provides a protocol for judgements on
sequence generation, allocation methods, blinding, incomplete
outcome data, selective outcome reporting and any other relevant
biases. We judged each of these domains at high, low or unclear
risk of bias according to Higgins 2011 and provided support for
each judgement. The conclusions are presented in a ’Risk of bias’
table. Any disagreements were resolved by discussion.
Measures of treatment effect
We planned to base the analysis on intention-to-treat data from
the individual clinical trials. The majority of outcomes were bi-
nary measures (mortality, morbidity, complications, adverse ef-
fects, characteristics of diagnosed cancer, frequency of an underly-
ing cancer diagnosis). For these outcomes, we computed odds ra-
tios (ORs) using a random-effects model and calculated the 95%
CI of the effect sizes. For time to cancer diagnosis, we aimed to
compute hazard ratios (HR), while for participant satisfaction, we
planned to report results descriptively (Deeks 2011).
Unit of analysis issues
The unit of analysis within each trial was the individual partici-
pant.
Dealing with missing data
We sought information about dropouts, withdrawals and other
missing data and, if not reported, we contacted the study authors.
Assessment of heterogeneity
We assessed heterogeneity between the pooled studies by visual
examination of the forest plot to check for overlapping CIs, and
used the Chi2 test for homogeneity with a 10% level of signiﬁ-
cance. We used the I2 statistic to measure the degree of inconsis-
tency between the studies. An I2 result of over 50% may represent
moderate to substantial heterogeneity (Deeks 2011).
Assessment of reporting biases
Weplanned to assess reporting biases such as publication bias using
funnel plots when there were more than 10 studies in the meta-
analyses (Sterne 2011). However, as there were only four studies
in the review it was not possible to test for funnel plot asymmetry.
Data synthesis
The review authors independently extracted the data. One review
author (LR) entered the data into Review Manager 5 (RevMan
2014). A second review author (SEY) cross-checked data entry and
resolved any discrepancies by consulting the source publication.
We used a random-effects model for meta-analysis of the data. We
planned to stratify analyses according to the individual cancer test
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being assessed and the combination of tests as used in the SOMIT
trial (Piccioli 2004a).
Subgroup analysis and investigation of heterogeneity
Where possible, we planned to analyse clinically relevant sub-
groups based on the following:
1. DVT or PE at time of randomisation;
2. cancer site;
3. treatment post-investigation with vitamin K antagonist or
LMWH;
4. duration of anticoagulation (e.g. three or six months);
5. age and gender of participants (comparing those in age and
gender groups for national screening programmes to those not in
these age and gender groups);
6. time of randomisation after VTE diagnosis (within three
months compared with after three months).
However, due to lack of data in the studies, it was not possible to
perform subgroup analysis.
Sensitivity analysis
We planned to conduct a sensitivity analysis by excluding studies
at high risk of bias to measure the effect on the results.
’Summary of findings’ table
We presented the main ﬁndings of the review results concerning
the quality of evidence, themagnitude of effect of the interventions
examined and the sum of available data for all outcomes of this
review (Types of outcome measures) in a ’Summary of ﬁndings’
table, according to the GRADE principles as described byHiggins
2011 and Atkins 2004. We calculated assumed control interven-
tion risks from the mean number of events in the control groups
of the selected studies for each outcome. We used the GRADE-
proﬁler ( GRADEpro) software to assist in the preparation of the
’Summary of ﬁndings’ table ( www.guidelinedevelopment.org).
R E S U L T S
Description of studies
Results of the search
No new studies were identiﬁed for inclusion in this 2018 update.
See Figure 1.
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Figure 1. Study flow diagram.
Included studies
Four studies fulﬁlled the eligibility criteria for inclusion in this re-
view (Carrier 2015; Piccioli 2004b; Prandoni 2016; Robin 2016).
See Characteristics of included studies table.
The ﬁrst study was a randomised multicentre study of 201 ap-
parently cancer-free people with acute unprovoked VTE (Piccioli
2004b). Extensive investigations for occult malignant disease were
compared with testing at the physician’s discretion. Ninety-nine
participants were randomised to the extensive screening group and
102 were randomised to the control group. Participants in the
extensive investigations group were offered ultrasound and CT
scans of the abdomen and pelvis, double contrast barium swallow-
ing, colonoscopy or sigmoidoscopy followed by a barium enema,
haemoccult test, sputum cytology and tumour markers including
carcinoembryonic antigen (CEA), alpha-fetoprotein (α-FP) and
CA125. Women also underwent mammography and Papanico-
laou (Pap) smears while men had transabdominal ultrasound of
the prostate and a total prostate-speciﬁc antigen (PSA) test. All
tests were completed within a four-week period from the diagnosis
of VTE. Participants in the control group were investigated at the
physician’s discretion. If the investigations suggested the presence
of a malignant process, further investigations were performed ac-
cording to current standards. Participants were followed up at 3,
12 and 24 months following the diagnosis of VTE. The primary
outcome was cancer-related morbidity, deﬁned as death due to a
malignant disease itself, or death due to complications of diag-
nostic or surgical procedures performed to diagnose or treat can-
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cer. A secondary outcome of this study consisted of the cluster of
cancer-related mortality and documented residual malignancy or
recurrent malignancy at 24 months. The authors also measured
the frequency of an underlying cancer diagnosis including type
and stage as well as mean time to cancer diagnosis.
The second study was a randomised study in which 195 partici-
pants with a ﬁrst episode of unprovoked VTE were randomised to
extensive investigations (98 participants) or a discretionary diag-
nostic approach excluding CT scans (97 participants) (Prandoni
2016). Extensive investigations comprised a mandatory CT scan
of the thorax, abdomen and pelvis together with faecal haemoccult
testing or any test at physician’s discretion according to good clin-
ical practice. Participants allocated to the discretionary diagnos-
tic approach or personalised strategy underwent additional testing
based on physicians’ judgements and participants’ preferences, in-
cluding a ’no-further testing’ option. Participants were followed
at 3, 6, 12 and 24 months to document the incidence of newly
discovered cancer and cancer-related mortality. The primary out-
comes were cancer-related mortality (deﬁned as death due to ma-
lignancy, or death due to the complications of the diagnostic or
surgical procedures performed to diagnose or treat cancer) and in-
cidence of newly discovered cancer. The secondary outcomes were
cancer stage, using the tumours-nodes-metastases classiﬁcation, at
which tumours were diagnosed in the two study groups and the
incidence of cancer-related mortality in the two randomisation
groups,
The third study was an open-label randomised study in which 854
participants with a ﬁrst episode of unprovoked VTE were ran-
domised to limited occult-cancer screening plus CT scanning of
the abdomen and pelvis (423 participants) or limited occult-can-
cer screening alone (431 participants) (Carrier 2015). The limited
occult-cancer screening comprised complete history and physical
examination, measurement of complete blood counts and serum
electrolyte and creatinine levels, liver-function testing and chest
radiography. Sex-speciﬁc screening was conducted if it had not
been performed in the previous year. A breast examination, mam-
mography, or both were performed in women over 50 years of
age and Pap testing and a pelvic examination were performed in
women 18 to 70 years of age who had ever been sexually active. A
prostate examination, PSA test, or both were performed in men
over 40 years of age. The additional CT investigations comprised
a virtual colonoscopy and gastroscopy, biphasic enhanced CT of
the liver, parenchymal pancreatography and uniphasic enhanced
CT of the distended bladder. Participants were followed up for
one year to document the incidence of newly diagnosed cancer,
type of cancer diagnosed, one-year cancer-related mortality, one-
year overall mortality, time to cancer diagnosis and incidence of
recurrent VTE.
The fourth study was an open-label randomised study in which
394 participants with a ﬁrst episode of unprovoked VTE were
randomised to a limited screening strategy (197 participants) or a
screening strategy consisting of the limited strategy plus an 18-ﬂu-
orodeoxyglucose (18F-FDG) PET/CT scan of the chest, abdomen
and pelvis (197 participants) (Robin 2016). The limited screening
comprised medical history taking, physical examination, routine
laboratory tests (including complete blood count, erythrocyte sed-
imentation rate or C-reactive protein, aminotransferases, alkaline
phosphatase and calcium), chest radiograph, recommended age-
speciﬁc and sex-speciﬁc cancer screening tests (i.e. PSA in men
older than 50 years, mammography in women older than 50 years
and Pap smear in all women). Participants were followed up for
two years to determine the proportion of people with a cancer
diagnosis in each group after the initial screening assessment.
Excluded studies
There were no studies excluded from the review. Studies that were
not randomised controlled trials were deemed not relevant and
therefore not listed as an excluded study.
Ongoing studies
There were no ongoing studies.
Risk of bias in included studies
See Figure 2 and Figure 3.
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Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
All four studies were randomised. Prandoni 2016 used envelopes.
Piccioli 2004b used aZelen approach (participants are randomised
to either the treatment or control group before giving informed
consent), Carrier 2015 used random number tables and Robin
2016 used a computer randomnumber generator. Therefore, these
four studies were judged at low risk of selection bias. In terms of
concealing the allocation of treatment, Piccioli 2004b performed
randomisation centrally and Carrier 2015 and Robin 2016 used
a central web-based randomisation system and, therefore, these
three were judged at low risk of selection bias. The Prandoni 2016
study used serially numbered, opaque, sealed envelopes to conceal
allocation and was, therefore, judged at low risk of selection bias
too.
Blinding
As the study groups in all four trials were randomised to extensive
screening or no further testing, it was impossible to blind partic-
ipants and study personnel. However, we believe it was unlikely
that the lack of blinding would have affected the outcome and,
therefore, all studies were judged at low risk of performance bias.
In Piccioli 2004b, the physician at the follow-up examination was
unaware of the allocation of participants and, therefore, detection
bias for outcome assessors was low. Similarly for Carrier 2015, a
blinded adjudication committee reviewed all suspected outcome
events and, therefore, the risk of detection bias was low. Robin
2016 did not blind outcome assessors to treatment allocation and
was, therefore, judged at high risk of detection bias. In Prandoni
2016, investigators performing the follow-up visits were blinded
to the participants’ randomisation group and the study was, there-
fore, judged at low risk of detection bias.
Incomplete outcome data
The treatment groups in all four studies were well-balanced with
respect to baseline characteristics, completionof the study protocol
and discontinuation of treatment. Furthermore, all missing data
were accounted for and reported. Therefore, all four studies were
judged at low risk of attrition bias (Carrier 2015; Piccioli 2004b;
Prandoni 2016; Robin 2016).
Selective reporting
All four studies clearly prespeciﬁed all primary and secondary out-
comes and data on all outcomes were reported (low risk of report-
ing bias) (Carrier 2015; Piccioli 2004b; Prandoni 2016; Robin
2016).
Other potential sources of bias
Two studies were deemed at low risk (Carrier 2015; Robin 2016),
and two studies were deemed to be at high risk of other bias
(Piccioli 2004b; Prandoni 2016). The study by Piccioli 2004b
was terminated early after the inclusion of only 201 participants
after ﬁve years for several reasons. First, only ﬁve of the more than
40 potential participating centres could contribute participants to
the study. Second, some medical ethics committees rejected the
protocol because of the absence of screening for occult cancer in
the control group, other centres could not start because the pro-
posed extensive screening was judged to be unethical. Finally, the
identiﬁcation of cancer at an apparent early stage in the extensive
screening group led to an increasing tendency among physicians
in the participating hospitals to initiate screening for cancer in the
control participants. The study by Prandoni 2016 was judged at
high risk of bias as results of an interim analysis, scheduled after
the inclusion of approximately half of the planned sample size,
showed no appreciable advantage of the CT-based strategy over
the control strategy for detection of occult cancers. In addition,
there was a low recruitment rate, so the study promoters decided
to terminate the study early.
Effects of interventions
See: Summary of findings for the main comparison Extensive
tests versus tests at the physician’s discretion;Summaryoffindings
2 Standard testing plus PET/CT scanning versus standard testing
alone
1. Extensive tests versus tests at the physician’s discretion
Two studies assessed the effect of testing for cancer versus clinically
indicated tests only (Piccioli 2004b; Prandoni 2016).
Both studies measured the primary outcome cancer-related mor-
tality. In Piccioli 2004b, 2/99 participants in the extensive testing
group died of cancer compared to 4/102 in the group who under-
went tests at the physician’s discretion (OR 0.51, 95% CI 0.09 to
2.82). In Prandoni 2016, 2/98 participants who underwent ex-
tensive testing and 4/97 participants who underwent tests at the
physician’s discretion died of cancer (OR 0.48, 95% CI 0.09 to
2.71). Meta-analysis showed anOR of 0.49 (95%CI 0.15 to 1.67;
low-quality evidence) in favour of extensive testing, which did not
reach statistical signiﬁcance (P = 0.26) (Analysis 1.1).
However, neither Piccioli 2004b nor Prandoni 2016 measured the
review’s other primary outcomes of all-cause mortality and VTE-
related mortality, or the secondary outcomes VTE-related mor-
bidity, complications of anticoagulation, adverse effects of cancer
tests, participant satisfaction and quality of life.
Piccioli 2004b looked at the location of themalignancy and found
no clear difference in the incidence of any particular cancer be-
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tween participants who underwent extensive tests and participants
who were tested at the physician’s discretion (lung: OR 2.08, 95%
CI 0.19 to 23.34; bladder: OR 2.08, 95%CI 0.19 to 23.34; stom-
ach: OR 1.03, 95% CI 0.06 to 16.71; kidney: OR 3.12, 95% CI
0.13 to 77.55; adrenal gland: OR 3.12, 95% CI 0.13 to 77.55;
liver: OR 3.12, 95% CI 0.13 to 77.55; uterus: OR 3.12, 95% CI
0.13 to 77.55; breast: OR 1.03, 95% CI 0.06 to 16.71; ovary:
OR 3.12, 95% CI 0.13 to 77.55; colon: OR 0.51, 95% CI 0.05
to 5.72; prostate: OR 0.51, 95% CI 0.05 to 5.72; pancreas: OR
0.20, 95% CI 0.01 to 4.26) (Analysis 1.2).
Piccioli 2004b compared the characteristics of the diagnosed can-
cer by assessing the proportion of early-stagemalignancies, deﬁned
as T1 or T2 without locoregional or distant metastases (N0 M0).
Overall, malignancies were less advanced in participants who had
undergone extensive testing. In total, 9/13 participants diagnosed
with cancer in the tested group had a T1- or T2-stage malignancy
without locoregional or distant metastases compared to 2/10 par-
ticipants diagnosed with cancer in the control group (OR 5.00,
95% CI 1.05 to 23.76; P = 0.04; low-quality evidence). There was
no difference in detection of advanced stages between groups: one
participant in the tested group had stage T3 compared with four
participants in the control group (OR 0.25, 95% CI 0.03 to 2.28;
P = 0.22; low-quality evidence) (Analysis 1.3).
One study measured time to cancer diagnosis (measured from the
time of diagnosis of VTE) (Piccioli 2004b), reported as a mean
of one month in tested participants compared to 11.6 months
in participants who were tested at the physician’s discretion (P
< 0.001). Standard deviations for the means were not given. We
attempted to contact the author for these data but received no
response.
Both studies measured the frequency of an underlying cancer diag-
nosis. Piccioli 2004b detected underlying cancer in 13/99 partici-
pants who underwent extensive testing, whereas it became symp-
tomatic in 10/102 control participants (OR 1.39, 95% CI 0.58
to 3.34). Prandoni 2016 detected cancer in 2/98 participants who
had further tests and it became apparent in 2/97 participants who
were tested at the physician’s discretion (OR 0.99, 95% CI 0.14 to
7.17). The combined incidence of an underlying cancer diagnosis
was 15/197 in the tested group and 12/199 in the control group
(OR 1.32, 95% CI 0.59 to 2.93; low-quality evidence) (Analysis
1.4). Therefore, after 24 months of follow-up, the incidence of
cancer was no different in the tested and control groups.
2. Standard testing plus PET/CT scanning versus standard
testing alone
Two studies assessed the effect of standard testing plus PET/
CT scanning versus standard testing alone (Carrier 2015; Robin
2016).
Both studies measured the primary outcome all-cause mortality.
In the standard testing plus CT scanning group, 11/620 partici-
pants died during follow-up compared to 9/628 participants who
received standard testing alone (OR 1.22, 95% CI 0.49 to 3.04;
moderate-quality evidence) (Analysis 2.1).
Carrier 2015 and Robin 2016 also measured cancer-related mor-
tality and reported an incidence of 6/620 participants with stan-
dard testing plus CT scanning compared to 11/628 participants
who received standard testing alone (OR 0.55, 95% CI 0.20 to
1.52; moderate-quality evidence) (Analysis 2.2).
The study by Carrier 2015 measured VTE-related morbidity. The
incidence of recurrent VTE was 14/423 participants who under-
went standard testing plus CT scanning compared to 14/431 par-
ticipants who had standard testing alone (OR 1.02, 95% CI 0.48
to 2.17; moderate-quality evidence) (Analysis 2.3).
Carrier 2015 and Robin 2016 also looked at the location of the
malignancy and found no clear difference in the incidence of any
particular cancer between the two groups (acute leukaemia: OR
1.62, 95% CI 0.20 to 13.22; gynaecological: OR 2.39, 95% CI
0.43 to 13.36; melanoma: OR 1.02, 95% CI 0.06 to 16.34; col-
orectal: OR 0.43, 95% CI 0.08 to 2.40; prostate: OR 2.52, 95%
CI 0.48 to 13.12; pancreatic: OR 4.81, 95% CI 0.55 to 42.48;
cholangiocarcinoma: OR 0.51, 95% CI 0.05 to 5.63; lymphoma:
OR 0.74, 95% CI 0.09 to 5.83; breast: OR 0.20, 95% CI 0.01 to
4.24; urological: OR 0.62, 95% CI 0.03 to 12.32; liver: OR 0.33,
95% CI 0.01 to 8.19; head and neck: OR 3.02, 95% CI 0.12 to
74.47; lung: OR 3.02, 95% CI 0.12 to 74.47; unknown primary
origin: OR 0.34, 95% CI 0.01 to 8.34) (Analysis 2.4).
Robin 2016 also measured the stage of cancer. Early-stage cancer
was detected in 7/197 participants who underwent standard test-
ing plus CT scanning compared to 4/197 participants who un-
derwent standard testing alone (OR 1.78, 95% CI 0.51 to 6.17;
low-quality evidence), while advanced-stage cancer was detected
in two participants in each group (OR 1.00, 95%CI 0.14 to 7.17;
low-quality evidence) (Analysis 2.5).
Time to cancer diagnosis was 4.0 months in the standard testing
plus PET/CT group and 4.2 months in the standard testing group
in one study (P = 0.88) (Carrier 2015). However, standard devi-
ations for these means were not given. We attempted to contact
the author for these data but received no response. Robin 2016
did not measure time to cancer diagnosis.
Carrier 2015 and Robin 2016 measured the frequency of under-
lying cancer diagnosis. Underlying cancer was detected in 30/620
participants who underwent standard testing plus CT scanning
compared to 18/628 participants who underwent standard testing
alone (OR 1.71, 95%CI 0.91 to 3.20; moderate-quality evidence)
(Analysis 2.6).
The studies by Carrier 2015 and Robin 2016 did not measure the
other review outcomes of VTE-related mortality, complications
of anticoagulation, adverse effects of cancer tests, participant sat-
isfaction or quality of life.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Standard testing plus PET/CT scanning versus standard testing alone
Patient or population: people with unprovoked VTE
Setting: hospital
Intervention: standard test ing + PET/ CT scanning
Comparison: standard test ing alone
Outcomes Anticipated absolute effects* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with standard
testing alone
Risk with standard
testing + PET/CT scan-
ning
All- cause mortality 1 Study populat ion OR 1.22
(0.49 to 3.04)
1248
(2 RCTs)
⊕⊕⊕©
Moderate 2
-
14 per 1000 17 per 1000
(7 to 42)
Cancer- related mortal-
ity 3
Study populat ion OR 0.55
(0.20 to 1.52)
1248
(2 RCTs)
⊕⊕⊕©
Moderate 2
-
18 per 1000 10 per 1000
(4 to 26)
VTE- related mortality 4 See comment See comment See comment See comment See comment No study measured this
outcome.
VTE- related morbidity
5
Study populat ion OR 1.02
(0.48 to 2.17)
854
(1 RCT)
⊕⊕⊕©
Moderate 6
-
32 per 1000 33 per 1000
(16 to 68)
Stage of cancer - early Study populat ion OR 1.78
(0.51 to 6.17)
394
(1 RCT)
⊕⊕©©
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20 per 1000 36 per 1000
(10 to 113)
Stage of cancer - ad-
vanced
Study populat ion OR 1.00
(0.14 to 7.17)
394
(1 RCT)
⊕⊕©©
Low 2,6
-
10 per 1000 10 per 1000
(1 to 69)
Time to cancer diagno-
sis 7
See comments See comments See comments 854
(1 RCT)
See comments Time to cancer diagno-
sis measured in Carrier
2015 as 4.2 months in
standard test ing group
and 4.0 months in stan-
dard test ing + PET/ CT
group (P = 0.88). How-
ever, standard devia-
t ions for these means
not given. Attempts
made to contact author
for these data but no re-
sponse received
Frequency of an under-
lying cancer diagnosis
8
Study populat ion OR 1.71
(0.91 to 3.20)
1248
(2 RCTs)
⊕⊕⊕©
Moderate 2
-
29 per 1000 48 per 1000
(26 to 86)
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; OR: odds rat io; PET/CT: positron emission tomography/ computed tomography; RCT: randomised controlled trial; VTE: venous thromboembolism.
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect.
Moderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent.
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect.
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect1
9
E
ffe
c
t
o
f
te
stin
g
fo
r
c
a
n
c
e
r
o
n
c
a
n
c
e
r-
o
r
v
e
n
o
u
s
th
ro
m
b
o
e
m
b
o
lism
(V
T
E
)-re
la
te
d
m
o
rta
lity
a
n
d
m
o
rb
id
ity
in
p
e
o
p
le
w
ith
u
n
p
ro
v
o
k
e
d
V
T
E
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
8
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
1 Death due to any cause.
2 Quality of evidence downgraded as risk of detect ion bias high for one study as outcome assessors not blinded to treatment
(Robin 2016).
3 Def ined as death due to malignant disease itself , or death due to complicat ions of treatments or procedures to diagnose or
treat cancer.
4 Fatal pulmonary embolism (PE). PE diagnosed ‘‘on the basis of a lung scan indicat ing a high probability of its presence,
as indicated by the presence of new or enlarged areas of segmental perfusion defects with vent ilat ion-perfusion mismatch;
an abnormal perfusion scan with documentat ion of new or recurrent deep vein thrombosis (DVT); the presence of non-
enhancing f ill ing defects in the central pulmonary vasculature on helical computed tomography; a f inding of intraluminal
f il l ing defects on pulmonary angiography; or evidence of f resh PE at autopsy’’ (Lee 2003b). Fatal PE including probable fatal
PE and unexplained sudden death used if reported, as def ined by individual studies.
5 Frequency of recurrent VTE. Recurrent PE or DVT diagnosed if a previously compressible proximal venous segment or
segments could no longer be compressed on ultrasonography or if there were constant intraluminal f il l ing defects in two or
more project ions on venography.
6 Quality of evidence downgraded for imprecision due to low number of events.
7 Time to cancer diagnosis, as def ined in included studies.
8 Frequency of an underlying cancer diagnosis (i.e. number of t imes cancer diagnosed through screening following an
unprovoked VTE as def ined in included studies) at t ime of VTE presentat ion and overall over follow-up period.
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D I S C U S S I O N
Summary of main results
Four studies fulﬁlled the eligibility criteria for inclusion in this re-
view (Carrier 2015; Piccioli 2004b; Prandoni 2016; Robin 2016).
In total, 1644 participants were studied. We found no studies that
were potentially eligible but then excluded.
Extensive tests versus tests at the physician’s
discretion
Two studies compared the effectiveness of testing for cancer on
cancer-related mortality in people with a ﬁrst unprovoked VTE
(Piccioli 2004b; Prandoni 2016). Piccioli 2004b performed an ex-
tensive list of tests while Prandoni 2016 carried out fewer tests.
Pooled analysis showed that testing for cancer was consistent with
either a beneﬁt or no beneﬁt on cancer-related mortality. Testing
did not increase the frequency of an underlying cancer diagnosis.
However, the time to cancer diagnosis was shorter in tested par-
ticipants (mean: one month with extensive tests versus 11 months
with tests at the physician’s discretion). Furthermore, more people
had a detection of early-stage cancer with extensive tests compared
to people who were tested at the physician’s discretion (Piccioli
2004b). However, standard deviations for the mean time to di-
agnosis were not reported and, therefore, it was impossible to in-
dependently test the statistical signiﬁcance of this result. Neither
study measured all-cause mortality, VTE-related morbidity and
mortality, adverse effects of anticoagulation, adverse effects of can-
cer tests, participant satisfaction or quality of life.
Standard testing plus PET/CT scanning versus
standard testing alone
Two studies compared limited screening plus PET/CT scanning
of the abdomen and pelvis with limited screening alone in people
with a ﬁrst unprovoked VTE (Carrier 2015; Robin 2016). Stan-
dard testing plus PET/CT scanning was consistent with either a
beneﬁt or no beneﬁt on all-cause mortality, cancer-related mortal-
ity and VTE-related morbidity. Extensive testing did not increase
the frequency of an underlying cancer diagnosis. Furthermore,
there was no clear difference in the incidence of particular types of
cancer or the stage of cancer between the extensive and standard
testing groups. One study measured time to cancer diagnosis but
standard deviations for the mean time to diagnosis were not re-
ported and, therefore, it was impossible to independently test the
statistical signiﬁcance of this result (Carrier 2015). Carrier 2015
and Robin 2016 did not measure VTE-related mortality, adverse
effects of anticoagulation, adverse effects of cancer tests, partici-
pant satisfaction or quality of life.
Overall completeness and applicability of
evidence
At present, there is limited evidence concerning whether testing
for undiagnosed cancer in people with a ﬁrst episode of unpro-
voked VTE (DVT or PE) is effective in reducing cancer- and
VTE-related mortality and morbidity and which tests for cancer
are most useful. Only four studies met the inclusion criteria for
this review (Carrier 2015; Piccioli 2004b; Prandoni 2016; Robin
2016). While the losses to follow-up were equally balanced within
each study, the number of participants in each study was relatively
small and pooled analysis is based on 1644 participants. Further-
more, the four studies primarily looked at cancer-related mortality
and incidence of cancer diagnosis as their main outcomes. Other
outcomes of interest for this review, such as VTE-related mor-
tality, adverse effects of anticoagulation, adverse effects of cancer
tests and quality of life, were not studied and, therefore, remain
unknown.
Quality of the evidence
One study included in the review was judged at low risk of bias
(Carrier 2015). Piccioli 2004b was judged at high risk of bias as
the studywas terminated early for several reasons. First, only ﬁve of
the more than 40 potential participating centres could contribute
participants to the study. Second, some medical ethics commit-
tees rejected the protocol because of the absence of screening for
occult cancer in the control group, other centres could not start
because the proposed extensive screening was judged to be un-
ethical. Finally, the identiﬁcation of cancer at an apparent early
stage in the extensive screening group led to an increasing ten-
dency among physicians in the participating hospitals to initiate
screening for cancer in the control participants. Prandoni 2016
was judged at low risk for all domains except other bias, where the
risk was deemed to be high as, based on an interim analysis, the
study was terminated early because of the low recruitment rate and
of the failure to show an appreciable advantage of the CT-based
strategy over the control strategy for detection of cancers. Robin
2016 was judged at low risk for all domains except detection bias,
where the risk was deemed high due to lack of blinding of outcome
assessors.
For the comparison extensive tests for cancer versus tests at the
physician’s discretion, the quality of the evidence for cancer-related
mortality and frequency of an underlying cancer diagnosis was
downgraded to low as there was a high risk of bias in both studies
due to them both being terminated early. However, the outcome
was direct and effect estimates were consistent and precise, as re-
ﬂected in the narrow CIs around the ORs (Summary of ﬁndings
for themain comparison). The quality of evidence for type of can-
cer are presented in a ’Summary of ﬁndings’ table (Appendix 2).
For type of cancer, the evidence was downgraded to low as there
was imprecision due to low number of events combined with the
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study being terminated early.
For the comparison standard testing plus PET/CT scanning versus
standard testing alone, the quality of the evidence was graded as
moderate for all-cause mortality and cancer-related mortality due
to the high risk of detection bias in Robin 2016. For VTE-related
morbidity, the quality of the evidence was downgraded to moder-
ate as only one study measured this outcome. For stage of cancer,
the evidence was downgraded to low as there was imprecision due
to low number of events and there was a high risk of detection
bias (Summary of ﬁndings 2). The quality of evidence for type of
cancer are presented in a summary of ﬁndings table in Appendix
3. For type of cancer, the evidence was judged to be moderate if
there was imprecision due to low number of events or where the
study was at high risk of detection bias. Where both imprecision
and detection bias occurred together, the quality of the evidence
was downgraded to low.
Potential biases in the review process
None of the authors of this review were involved in any of the
included or excluded studies. Furthermore, none have any com-
mercial or other conﬂict of interest. The search was as compre-
hensive as possible, and all studies were independently assessed for
inclusion by two review authors. We are conﬁdent that we have
included all relevant studies and we have attempted to reduce bias
in the review process by performing data extraction and assessing
study quality independently.However, the possibility remains that
we may have missed studies that have not been published.
We judged blinding of investigators and participants to be at low
risk of bias. It would have been impossible to blind participants
and staff to tests such as scans. Therefore, there is a risk of cross-
over bias in participants in the control group with them having
further tests. However, the effect of this would be to minimise the
apparent beneﬁt from testing that was observed, and, therefore,
this does not detract from the conclusions of the study or review.
In this review, we presented the studies by Piccioli 2004b and
Prandoni 2016 together as both studies compared extensive tests
for cancer versus “tests at the physicians discretion”. The studies by
Carrier 2015 and Robin 2016 were reported in a separate analysis
as both studies compared limited screening plus PET/CT scanning
versus limited screening alone. Combining all four studies in a
meta-analysis would have been problematic due to the different
deﬁnitions of the comparator groups. However, the control group
of the Carrier 2015 and Robin 2016 studies included some of
the tests in the test group of the studies by Piccioli 2004b and
Prandoni 2016, which may account for why there was no clear
difference observed, along with participation of all people in breast
and colorectal cancer screening programmes. This may also be the
reason for the very low incidence of cancer in the studies by Carrier
2015 and Robin 2016 compared to the studies by Piccioli 2004b
and Prandoni 2016.
Agreements and disagreements with other
studies or reviews
To date, three other systematic reviews have assessed the effective-
ness of testing for cancer on cancer-relatedmortality in peoplewith
an unprovoked VTE. van Es 2017 conducted a systematic review
and meta-analysis of individual patient data from ten prospective
studies. Only two of these were RCTs, both of which were also
included in our meta-analysis (Carrier 2015; Robin 2016). The
primary outcome was prevalence of occult cancer in patients with
an unprovoked VTE. The prevalence of cancer 12 months after
VTE diagnosis was 5.2% (95% CI 4.1% to 6.5%). The preva-
lence of cancer was higher in patients who had extensive testing
than in those who had more limited testing initially (OR 2.0,
95% CI 1.2 to 3.4) but not at 12 months (OR 1.4 95% CI 0.89
to 2.1). Furthermore the prevalence of cancer increased with age,
and was seven-fold higher in patients aged 50 years or older, than
in younger patients (OR 7.1, 95% CI 3.1 to 16.0). Systematic
reviews by Klein 2017 and Zhou 2017 evaluated the efﬁcacy of an
extensive testing strategy for occult malignant diseases in patients
with unprovoked VTE. Both reviews included ﬁve studies; the
same four studies included in our review (Carrier 2015; Piccioli
2004b; Prandoni 2016; Robin 2016) and a ﬁfth study which was a
prospective cohort study (vanDoormaal 2011). This did not meet
the inclusion criteria for our review as we considered RCTs only.
Neither review demonstrated a signiﬁcant difference between ex-
tensive and limited testing for all cause mortality (with risk ratios
(RR) of 0.86, 95% CI 0.58 to 1.27 and RR 0.86, 95% CI, 0.58
to1.27 for Klein 2017 and Zhou 2017, respectively), nor cancer-
related mortality (RR 0.93, 95% CI 0.54 to 1.58 and RR 0.86,
95% CI, 0.46 to 1.62 for Klein 2017 and Zhou 2017, respec-
tively). Zhou 2017 found no signiﬁcant difference between the
extensive and limited testing groups with regard to risk of missed
cancer diagnosis (RR 0.51, 95% CI 0.20 to 1.28). However, Klein
2017 determined that extensive testing yielded more diagnoses of
cancer (RR 2.17, 95% CI 1.42 to 3.32).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
At present, there is insufﬁcient evidence as to whether testing for
undiagnosed cancer in people with a ﬁrst episode of unprovoked
venous thromboembolism (VTE) (deep vein thrombosis (DVT)
of the lower limb or pulmonary embolism (PE)) is effective in
reducing cancer- and VTE-related mortality and morbidity, and
which tests for cancer are best at identifying treatable cancers early.
The decision whether to screen for cancer or not in a ﬁrst episode
of unprovoked VTE remains for individual clinicians and partici-
pants to decide on a case-by-case basis. The diagnosis of cancer has
signiﬁcant implications for participants and may alter the phar-
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macological treatment of their VTE, and some may wish to be
investigated even in the absence of a survival beneﬁt.
Implications for research
The low number of studies in this systematic review conﬁrms the
need for further methodologically sound and large randomised
controlled trials. They should be adequately powered to look at
key endpoints including mortality, as well as addressing questions
concerning the types of test to be used, quality of life and partici-
pant preference.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Carrier 2015
Methods Study design: multicentre, open-label, randomised controlled trial
Source of funding: Heart and Stroke Foundation of Canada.
Participants Country: Canada.
Setting: hospital.
Number of centres: 9.
Number of participants: 854.
Age (mean (SD)): screening + CT group: 53.4 (14.2) years; screening only group: 53.7
(13.8)
Sex: screening + CT group: 299 M/124 F; screening only group: 277 M/154 F
Inclusion criteria: people with new diagnosis of ﬁrst unprovoked VTE (proximal lower-
limb deep vein thrombosis, pulmonary embolism, or both). Unprovoked VTE deﬁned
as VTE in absence of known overt active cancer, current pregnancy, thrombophilia
(hereditary or acquired), previous unprovoked VTE or a temporary predisposing factor
in the previous 3 months, including paralysis, paresis or plaster immobilisation of the
legs, conﬁnement to bed for ≥ 3 days or major surgery
Exclusion criteria: aged < 18 years, refusal or inability to provide informed consent,
allergy to contrast media, creatinine clearance < 60 mL per minute, claustrophobia or
agoraphobia, weight > 130 kg, ulcerative colitis or glaucoma
Interventions Screening procedure: complete history and physical examination, measurement of com-
plete blood counts and serum electrolyte and creatinine levels, liver-function testing
and chest radiography. Sex-speciﬁc screening conducted if it had not been performed in
previous year. Breast examination, mammography, or both performed in women > 50
years of age and Pap testing and a pelvic examination performed in women 18-70 years
of age who had never been sexually active. Prostate examination, PSA test, or both per-
formed in men aged > 40 years. Also comprehensive CT of abdomen and pelvis (virtual
colonoscopy and gastroscopy, biphasic enhanced CT of liver, parenchymal pancreatog-
raphy, and uniphasic enhanced CT of distended bladder)
Control: complete history and physical examination, measurement of complete blood
counts and serum electrolyte and creatinine levels, liver-function testing and chest ra-
diography. Sex-speciﬁc screening conducted if it had not been performed in previous
year. Breast examination, mammography, or both performed in women > 50 years of
age and Pap testing and a pelvic examination performed in women 18-70 years of age
who had ever been sexually active. Prostate examination, PSA test, or both performed in
men aged > 40 years
Duration: 1 year follow-up.
Outcomes Primary outcomes: newly diagnosed cancer during the follow-up period in people who
had a negative screening result for occult cancer
Secondary outcomes: total number of occult cancers diagnosed and total number of early
cancers (T1−2, N0, M0 according to theWorld Health Organization TNM classiﬁcation
system) diagnosed by occult-cancer screening and during subsequent 1-year follow-up,
1-year cancer-related mortality, 1-year overall mortality, time to cancer diagnosis and
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Carrier 2015 (Continued)
incidence of recurrent VTE
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The trial statistician generated the
randomisation list using random-number
tables.”
Allocation concealment (selection bias) Low risk Quote: “A central Web-based randomisa-
tion system ensured assignment conceal-
ment.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: blinding of participants and
study personnel not done but review au-
thors judged that outcome and outcome
measurement not likely to be inﬂuenced by
lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “A central adjudication committee
whosemembers were unaware of the study-
group assignments reviewed all suspected
outcome events.”
Comment: outcome assessors blinded to
study allocation.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: all losses to follow-up ac-
counted for.
Selective reporting (reporting bias) Low risk Comment: primary and secondary out-
comes clearly prespeciﬁed and reported
Other bias Low risk Comment: study appeared free from other
sources of bias.
Piccioli 2004b
Methods Study design: randomised multicentre clinical trial.
Source of funding: Associazone Italiana per le Ricerca sul Cancro
Participants Country: Italy.
Setting: hospital.
Number of centres: not stated.
Number of participants: 201.
Age (mean (SD)): screening group: 66.2 (13.1) years; no screening group: 66.6 (13.1)
years
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Piccioli 2004b (Continued)
Sex: screening group: 54 M/45 F; no screening group: 46 M/56 F
Inclusion criteria: apparently cancer-free people with a documented unprovoked ﬁrst
episode of symptomatic deep vein thrombosis of the lower extremity or pulmonary
embolism
Exclusion criteria: recognised risk factor for VTE (malignant disease, trauma of the
leg, surgical procedures or immobilisation within 6 months, conﬁrmed spontaneous
VTE in a ﬁrst-degree relative, deﬁciency of antithrombin, protein C or S, presence
of circulating lupus anticoagulant, oestrogen use, pregnancy or childbirth), previously
documented VTE, malignant disease identiﬁed at routine physical examination, history
taking, laboratory assessment or chest X-ray at referral, unable to attend follow-up due
to geographic inaccessibility and aged < 25 years
Interventions Screening procedure: combination of ultrasound and CT scan of abdomen and pelvis,
gastroscopy or double-contrast barium swallow, ﬂexible sigmoidoscopy or rectoscopy
followed by barium enema or colonoscopy, haemoccult, sputum cytology and tumour
markers including carcinoembryonic antigen, α-fetoprotein and CA125. In addition,
women had gynaecological examination, Pap smear and mammography. Men had a
transabdominal ultrasound of prostate and total PSA test
Control: tests at physician’s discretion.
Duration: 2-year follow-up. At these visits, special attention paid to recent medical
history. To avoid diagnostic suspicion bias, medical history concerning general health,
hospital admission, and occurrence of signs and symptoms of cancer obtained on a
standardised form by a physician unaware of allocation of participant. If malignant
disease had become apparent during follow-up, information from the attending specialist
sought after consent of participant
Outcomes Primary outcomes: cancer-related mortality deﬁned as death due to a malignant disease
itself, or death due to complications of diagnostic or surgical procedures performed to
diagnose or treat cancer
Secondary outcomes: cluster of cancer-related mortality and presence of objectively doc-
umented residual malignancy or recurrent malignancy at 24 months and sensitivity of
the diagnostic work-up for occult malignancy
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “According to the Zelen design, pa-
tients randomised to...”
Allocation concealment (selection bias) Low risk Quote: “Randomisation was performed
centrally.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Patients randomised to extensive
screening were informed about the study.
As patients allocated to the control group
were not informed about the study, patients
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Piccioli 2004b (Continued)
and their physicians were not discouraged
to search for malignant disease.”
Comment: blinding of participants in ex-
tensive screening group and study person-
nel not done but review authors judged that
outcome and outcome measurement not
likely to be inﬂuenced by lack of blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “To avoid diagnostic suspicion bias,
the medical history concerning general
health, hospital admission and occurrence
of signs and symptoms of cancer were ob-
tained on a standardised form by a physi-
cian unaware of allocation of the patient.”
Comment: outcome assessors blinded to
study allocation.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: all participants completed the
2-year follow-up. No missing data
Selective reporting (reporting bias) Low risk Comment: primary and secondary out-
comes clearly prespeciﬁed and reported
Other bias High risk Comment: study terminated early after in-
clusion of only 201 participants after 5
years for several reasons. First, only 5 of
the more than 40 potential participating
centres could contribute participants to the
study. Second, some medical ethics com-
mittees rejected the protocol because of the
absence of screening for occult cancer in the
control group, other centres could not start
because the proposed extensive screening
was judged to be unethical. Finally, identi-
ﬁcation of cancer at an apparent early stage
in the extensive screening group led to an
increasing tendency among physicians in
participating hospitals to initiate screening
for cancer in control participants
Prandoni 2016
Methods Study design: multicentre, randomised controlled trial.
Participants Country: Italy.
Setting: hospital.
Number of centres: 5.
Number of participants: 195
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Prandoni 2016 (Continued)
Age (mean (SD)): extensive screening group: 69.3 (14) years; control group: 69.0 (14)
years
Sex: extensive screening group: 54 M/44 F; control group: 47 M/50 F
Inclusion criteria: people with an objectively diagnosed, ﬁrst episode of unprovoked
VTE, in whom a routine initial screening for cancer was normal
Exclusion criteria: history of previous documented episodes of VTE, aged < 18 years,
pregnant, unable to attend follow-up visits because of geographic inaccessibility, had
known allergy to contrast medium or had a CT scan of torso for any reasons within 6
months from presentation
Interventions Screening procedure: extensive screening with mandatory CT scan of thorax, abdomen
and pelvis together with haemoccult test or any test at physician’s discretion according
to good clinical practice
Control: personalised strategy consisting of additional testing based on physicians’ judge-
ments and participants’ preferences, including a ’no-further testing’ option
Duration: 3, 6, 12 and 24months’ follow-up in which participants were asked about gen-
eral health, history of recent hospital admissions and occurrence of signs and symptoms
suggestive of cancer. Cancer outcomes that presented during follow-up were detected
based on clinical features that would prompt diagnostic imaging or cancers that were
occasionally detected by screening that was independent of the diagnosis of VTE
Outcomes Primary outcomes: cancer-relatedmortality (deﬁned as death due tomalignancy or death
due to the complications of the diagnostic or surgical procedures performed to diagnose
or treat cancer) and incidence of newly discovered cancer
Secondary outcomes: cancer stage, using the TNM classiﬁcation, at which tumours were
diagnosed in the 2 study groups; and incidence of cancer-related mortality in the 2
randomisation groups
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “Concealed allocation was ensured
by employing serially numbered, opaque,
sealed envelopes. Each participating centre
was initially assigned a lot of 20 envelopes,
while subsequent allocations were in lots of
10, as needed.”
Allocation concealment (selection bias) Low risk Quote: “Concealed allocation was ensured
by employing serially numbered, opaque,
sealed envelopes. Each participating centre
was initially assigned a lot of 20 envelopes,
while subsequent allocations were in lots of
10, as needed.”
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Prandoni 2016 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Comment: blinding of participants in ex-
tensive screening group and study person-
nel not done but review authors judged that
outcome and outcome measurement were
not likely to be inﬂuenced by lack of blind-
ing
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Comment: investigators performing the
follow-up visits blinded to participants’
randomisation groups’
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: all losses to follow-up ac-
counted for.
Selective reporting (reporting bias) Low risk Comment: primary and secondary out-
comes clearly prespeciﬁed and reported
Other bias High risk Comment: interim analysis scheduled after
inclusion of approximately half of planned
sample size. Based on results of this analy-
sis, study promoters decided to stop study
enrolment because of low recruitment rate
and of failure to show an appreciable ad-
vantage of CT-based strategy over control
strategy for detection of occult cancers
Robin 2016
Methods Study design: open-label, multicentre, randomised study.
Source of funding: Programme Hospitalier de Recherche Clinique (French Department
of Health)
Participants Country: France.
Setting: hospital.
Number of centres: 4.
Number of participants: 394.
Age (mean (range)): screening group: 64 (48-77) years; limited screening group: 62 (50-
75) years
Sex: screening group: 105 M/92 F; limited screening group: 102 M/95 F
Inclusion criteria: aged ≥ 18 years, diagnosed with unprovoked VTE. VTE deﬁned as
objectively conﬁrmed proximal deep vein thrombosis or pulmonary embolism. Unpro-
voked VTE deﬁned as VTE not provoked by major inherited or acquired risk factor
including surgery, trauma or fracture during 3 months before VTE event, known an-
tiphospholipid antibody syndrome or known deﬁciency in antithrombin, protein C or
protein S
Exclusion criteria: ongoing pregnancy, active malignant disease (deﬁned as known ma-
lignant disease which was active or treated during previous 5 years), not insured under
French National Social Security programme, hypersensitivity to 18F-FDG or any of the
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Robin 2016 (Continued)
excipients according to summary of product characteristics in France, or unable or un-
willing to give consent
Interventions Screening procedure: screening strategy consisting of limited strategy + 18F-FDG PET/
CT scan of chest, abdomen and pelvis.
Control: limited screening strategy (physical examination, usual laboratory tests and
basic radiographs)
Duration: 2 years.
Outcomes Primary outcomes: proportion of people with a cancer diagnosis in each group after the
initial screening assessment
Secondary outcomes: subsequent cancer diagnosis in people with negative initial screen-
ing, proportion of early-stage versus advanced-stage tumours at initial screening and
during follow-up, overall mortality and cancer-related mortality during follow-up
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quote: “The randomisation list was created
centrally using computer-generated block
sizes of six, stratiﬁed by centre, and con-
cealed from investigators.We used a secure,
dedicated, central web-based randomisa-
tion system (Clinsight).”
Allocation concealment (selection bias) Low risk Quote: “The randomisation list was created
centrally using computer-generated block
sizes of six, stratiﬁed by centre, and con-
cealed from investigators.We used a secure,
dedicated, central web-based randomisa-
tion system (Clinsight). A unique study
participant number and study group allo-
cation was given after patients’ basic infor-
mation and eligibility criteria were entered
by the study personnel.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Participants and physicians giving
the intervention, assessing outcomes, and
analysing the datawere notmasked to study
group assignment.”
Comment: blinding of participants and
study personnel not done but review au-
thors judged that outcome and outcome
measurement not likely to be inﬂuenced by
lack of blinding
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Robin 2016 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Quote: “Physicians giving the intervention,
assessing outcomes, and analysing the data
were not masked to study group assign-
ment.”
Comment: outcome assessors not blinded
to outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: all losses to follow-up ac-
counted for.
Selective reporting (reporting bias) Low risk Comment: primary and secondary out-
comes clearly prespeciﬁed and reported
Other bias Low risk Comment: study appeared free from other
sources of bias.
CT: computed tomography; F: female; FDG: ﬂuorodeoxyglucose; M: male; Pap: Papanicolaou; PET: positron emission tomography;
PSA: prostate-speciﬁc antigen; SD: standard deviation; TNM: tumour-node-metastasis; VTE: venous thromboembolism.
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D A T A A N D A N A L Y S E S
Comparison 1. Extensive tests versus tests at the physician’s discretion
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cancer-related mortality 2 396 Odds Ratio (M-H, Random, 95% CI) 0.49 [0.15, 1.67]
2 Characteristics of diagnosed
cancer: type of cancer
1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
2.1 Lung 1 201 Odds Ratio (M-H, Random, 95% CI) 2.08 [0.19, 23.34]
2.2 Bladder 1 201 Odds Ratio (M-H, Random, 95% CI) 2.08 [0.19, 23.34]
2.3 Stomach 1 201 Odds Ratio (M-H, Random, 95% CI) 1.03 [0.06, 16.71]
2.4 Kidney 1 201 Odds Ratio (M-H, Random, 95% CI) 3.12 [0.13, 77.55]
2.5 Adrenal gland 1 201 Odds Ratio (M-H, Random, 95% CI) 3.12 [0.13, 77.55]
2.6 Liver 1 201 Odds Ratio (M-H, Random, 95% CI) 3.12 [0.13, 77.55]
2.7 Uterus 1 201 Odds Ratio (M-H, Random, 95% CI) 3.12 [0.13, 77.55]
2.8 Breast 1 201 Odds Ratio (M-H, Random, 95% CI) 1.03 [0.06, 16.71]
2.9 Ovary 1 201 Odds Ratio (M-H, Random, 95% CI) 3.12 [0.13, 77.55]
2.10 Colon 1 201 Odds Ratio (M-H, Random, 95% CI) 0.51 [0.05, 5.72]
2.11 Prostate 1 201 Odds Ratio (M-H, Random, 95% CI) 0.51 [0.05, 5.72]
2.12 Pancreas 1 201 Odds Ratio (M-H, Random, 95% CI) 0.20 [0.01, 4.26]
3 Characteristics of diagnosed
cancer: stage of cancer
1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
3.1 T1 or T2 (N0 M0) 1 201 Odds Ratio (M-H, Random, 95% CI) 5.00 [1.05, 23.76]
3.2 T3 1 201 Odds Ratio (M-H, Random, 95% CI) 0.25 [0.03, 2.28]
4 Frequency of underlying cancer
diagnosis
2 396 Odds Ratio (M-H, Random, 95% CI) 1.32 [0.59, 2.93]
Comparison 2. Standard testing plus PET/CT scanning versus standard testing alone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality 2 1248 Odds Ratio (M-H, Random, 95% CI) 1.22 [0.49, 3.04]
2 Cancer-related mortality 2 1248 Odds Ratio (M-H, Random, 95% CI) 0.55 [0.20, 1.52]
3 Venous
thromboembolism-related
morbidity
1 854 Odds Ratio (M-H, Random, 95% CI) 1.02 [0.48, 2.17]
4 Characteristics of diagnosed
cancer: type of cancer
2 Odds Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Acute leukaemia 2 1248 Odds Ratio (M-H, Random, 95% CI) 1.62 [0.20, 13.22]
4.2 Gynaecological 2 1248 Odds Ratio (M-H, Random, 95% CI) 2.39 [0.43, 13.36]
4.3 Skin: melanoma 1 854 Odds Ratio (M-H, Random, 95% CI) 1.02 [0.06, 16.34]
4.4 Colorectal 2 1248 Odds Ratio (M-H, Random, 95% CI) 0.43 [0.08, 2.40]
4.5 Prostate 2 1248 Odds Ratio (M-H, Random, 95% CI) 2.52 [0.48, 13.12]
4.6 Pancreatic 2 1248 Odds Ratio (M-H, Random, 95% CI) 4.81 [0.55, 42.48]
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4.7 Cholangiocarcinoma 1 854 Odds Ratio (M-H, Random, 95% CI) 0.51 [0.05, 5.63]
4.8 Lymphoma 2 1248 Odds Ratio (M-H, Random, 95% CI) 0.74 [0.09, 5.83]
4.9 Breast 1 854 Odds Ratio (M-H, Random, 95% CI) 0.20 [0.01, 4.24]
4.10 Urological 2 1248 Odds Ratio (M-H, Random, 95% CI) 0.62 [0.03, 12.32]
4.11 Liver 1 394 Odds Ratio (M-H, Random, 95% CI) 0.33 [0.01, 8.19]
4.12 Head and neck 1 394 Odds Ratio (M-H, Random, 95% CI) 3.02 [0.12, 74.47]
4.13 Lung 1 394 Odds Ratio (M-H, Random, 95% CI) 3.02 [0.12, 74.47]
4.14 Unknown primary 1 854 Odds Ratio (M-H, Random, 95% CI) 0.34 [0.01, 8.34]
5 Characteristics of diagnosed
cancer: stage of cancer
1 Odds Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Early 1 394 Odds Ratio (M-H, Random, 95% CI) 1.78 [0.51, 6.17]
5.2 Advanced 1 394 Odds Ratio (M-H, Random, 95% CI) 1.0 [0.14, 7.17]
6 Frequency of an underlying
cancer diagnosis
2 1248 Odds Ratio (M-H, Random, 95% CI) 1.71 [0.91, 3.20]
Analysis 1.1. Comparison 1 Extensive tests versus tests at the physician’s discretion, Outcome 1 Cancer-
related mortality.
Review: Effect of testing for cancer on cancer- or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE
Comparison: 1 Extensive tests versus tests at the physician’s discretion
Outcome: 1 Cancer-related mortality
Study or subgroup Extensive tests Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Piccioli 2004b 2/99 4/102 50.0 % 0.51 [ 0.09, 2.82 ]
Prandoni 2016 2/98 4/97 50.0 % 0.48 [ 0.09, 2.71 ]
Total (95% CI) 197 199 100.0 % 0.49 [ 0.15, 1.67 ]
Total events: 4 (Extensive tests), 8 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours extensive tests Favours control
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Analysis 1.2. Comparison 1 Extensive tests versus tests at the physician’s discretion, Outcome 2
Characteristics of diagnosed cancer: type of cancer.
Review: Effect of testing for cancer on cancer- or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE
Comparison: 1 Extensive tests versus tests at the physician’s discretion
Outcome: 2 Characteristics of diagnosed cancer: type of cancer
Study or subgroup Extensive tests Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Lung
Piccioli 2004b 2/99 1/102 100.0 % 2.08 [ 0.19, 23.34 ]
Subtotal (95% CI) 99 102 100.0 % 2.08 [ 0.19, 23.34 ]
Total events: 2 (Extensive tests), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
2 Bladder
Piccioli 2004b 2/99 1/102 100.0 % 2.08 [ 0.19, 23.34 ]
Subtotal (95% CI) 99 102 100.0 % 2.08 [ 0.19, 23.34 ]
Total events: 2 (Extensive tests), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
3 Stomach
Piccioli 2004b 1/99 1/102 100.0 % 1.03 [ 0.06, 16.71 ]
Subtotal (95% CI) 99 102 100.0 % 1.03 [ 0.06, 16.71 ]
Total events: 1 (Extensive tests), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
4 Kidney
Piccioli 2004b 1/99 0/102 100.0 % 3.12 [ 0.13, 77.55 ]
Subtotal (95% CI) 99 102 100.0 % 3.12 [ 0.13, 77.55 ]
Total events: 1 (Extensive tests), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
5 Adrenal gland
Piccioli 2004b 1/99 0/102 100.0 % 3.12 [ 0.13, 77.55 ]
Subtotal (95% CI) 99 102 100.0 % 3.12 [ 0.13, 77.55 ]
Total events: 1 (Extensive tests), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
6 Liver
Piccioli 2004b 1/99 0/102 100.0 % 3.12 [ 0.13, 77.55 ]
0.001 0.01 0.1 1 10 100 1000
Favours control Favours extensive tests
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(. . . Continued)
Study or subgroup Extensive tests Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 99 102 100.0 % 3.12 [ 0.13, 77.55 ]
Total events: 1 (Extensive tests), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
7 Uterus
Piccioli 2004b 1/99 0/102 100.0 % 3.12 [ 0.13, 77.55 ]
Subtotal (95% CI) 99 102 100.0 % 3.12 [ 0.13, 77.55 ]
Total events: 1 (Extensive tests), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
8 Breast
Piccioli 2004b 1/99 1/102 100.0 % 1.03 [ 0.06, 16.71 ]
Subtotal (95% CI) 99 102 100.0 % 1.03 [ 0.06, 16.71 ]
Total events: 1 (Extensive tests), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
9 Ovary
Piccioli 2004b 1/99 0/102 100.0 % 3.12 [ 0.13, 77.55 ]
Subtotal (95% CI) 99 102 100.0 % 3.12 [ 0.13, 77.55 ]
Total events: 1 (Extensive tests), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.69 (P = 0.49)
10 Colon
Piccioli 2004b 1/99 2/102 100.0 % 0.51 [ 0.05, 5.72 ]
Subtotal (95% CI) 99 102 100.0 % 0.51 [ 0.05, 5.72 ]
Total events: 1 (Extensive tests), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.59)
11 Prostate
Piccioli 2004b 1/99 2/102 100.0 % 0.51 [ 0.05, 5.72 ]
Subtotal (95% CI) 99 102 100.0 % 0.51 [ 0.05, 5.72 ]
Total events: 1 (Extensive tests), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.59)
12 Pancreas
Piccioli 2004b 0/99 2/102 100.0 % 0.20 [ 0.01, 4.26 ]
Subtotal (95% CI) 99 102 100.0 % 0.20 [ 0.01, 4.26 ]
Total events: 0 (Extensive tests), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
0.001 0.01 0.1 1 10 100 1000
Favours control Favours extensive tests
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Analysis 1.3. Comparison 1 Extensive tests versus tests at the physician’s discretion, Outcome 3
Characteristics of diagnosed cancer: stage of cancer.
Review: Effect of testing for cancer on cancer- or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE
Comparison: 1 Extensive tests versus tests at the physician’s discretion
Outcome: 3 Characteristics of diagnosed cancer: stage of cancer
Study or subgroup Extensive tests Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 T1 or T2 (N0 M0)
Piccioli 2004b 9/99 2/102 100.0 % 5.00 [ 1.05, 23.76 ]
Subtotal (95% CI) 99 102 100.0 % 5.00 [ 1.05, 23.76 ]
Total events: 9 (Extensive tests), 2 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.02 (P = 0.043)
2 T3
Piccioli 2004b 1/99 4/102 100.0 % 0.25 [ 0.03, 2.28 ]
Subtotal (95% CI) 99 102 100.0 % 0.25 [ 0.03, 2.28 ]
Total events: 1 (Extensive tests), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
Test for subgroup differences: Chi2 = 4.72, df = 1 (P = 0.03), I2 =79%
0.001 0.01 0.1 1 10 100 1000
Favours control Favours extensive tests
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Analysis 1.4. Comparison 1 Extensive tests versus tests at the physician’s discretion, Outcome 4 Frequency
of underlying cancer diagnosis.
Review: Effect of testing for cancer on cancer- or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE
Comparison: 1 Extensive tests versus tests at the physician’s discretion
Outcome: 4 Frequency of underlying cancer diagnosis
Study or subgroup Extenisve tests Control Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Piccioli 2004b 13/99 10/102 83.7 % 1.39 [ 0.58, 3.34 ]
Prandoni 2016 2/98 2/97 16.3 % 0.99 [ 0.14, 7.17 ]
Total (95% CI) 197 199 100.0 % 1.32 [ 0.59, 2.93 ]
Total events: 15 (Extenisve tests), 12 (Control)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.09, df = 1 (P = 0.76); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours control Favours extensive tests
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Analysis 2.1. Comparison 2 Standard testing plus PET/CT scanning versus standard testing alone, Outcome
1 All-cause mortality.
Review: Effect of testing for cancer on cancer- or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE
Comparison: 2 Standard testing plus PET/CT scanning versus standard testing alone
Outcome: 1 All-cause mortality
Study or subgroup
Standard
testing +
CT
Standard
testing
alone Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Carrier 2015 5/423 6/431 57.9 % 0.85 [ 0.26, 2.80 ]
Robin 2016 6/197 3/197 42.1 % 2.03 [ 0.50, 8.24 ]
Total (95% CI) 620 628 100.0 % 1.22 [ 0.49, 3.04 ]
Total events: 11 (Standard testing + CT), 9 (Standard testing alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.87, df = 1 (P = 0.35); I2 =0.0%
Test for overall effect: Z = 0.44 (P = 0.66)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours standard + CT Favours standard alone
40Effect of testing for cancer on cancer- or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked
VTE (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.2. Comparison 2 Standard testing plus PET/CT scanning versus standard testing alone, Outcome
2 Cancer-related mortality.
Review: Effect of testing for cancer on cancer- or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE
Comparison: 2 Standard testing plus PET/CT scanning versus standard testing alone
Outcome: 2 Cancer-related mortality
Study or subgroup
Standard
testing +
CT
Standard
testing
alone Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Carrier 2015 4/423 6/431 62.8 % 0.68 [ 0.19, 2.41 ]
Robin 2016 2/197 5/197 37.2 % 0.39 [ 0.08, 2.05 ]
Total (95% CI) 620 628 100.0 % 0.55 [ 0.20, 1.52 ]
Total events: 6 (Standard testing + CT), 11 (Standard testing alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours standard + CT Favours standard alone
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Analysis 2.3. Comparison 2 Standard testing plus PET/CT scanning versus standard testing alone, Outcome
3 Venous thromboembolism-related morbidity.
Review: Effect of testing for cancer on cancer- or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE
Comparison: 2 Standard testing plus PET/CT scanning versus standard testing alone
Outcome: 3 Venous thromboembolism-related morbidity
Study or subgroup
Standard
testing +
CT
Standard
testing
alone Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Carrier 2015 14/423 14/431 100.0 % 1.02 [ 0.48, 2.17 ]
Total (95% CI) 423 431 100.0 % 1.02 [ 0.48, 2.17 ]
Total events: 14 (Standard testing + CT), 14 (Standard testing alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours standard + CT Favours standard alone
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Analysis 2.4. Comparison 2 Standard testing plus PET/CT scanning versus standard testing alone, Outcome
4 Characteristics of diagnosed cancer: type of cancer.
Review: Effect of testing for cancer on cancer- or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE
Comparison: 2 Standard testing plus PET/CT scanning versus standard testing alone
Outcome: 4 Characteristics of diagnosed cancer: type of cancer
Study or subgroup
Standard
testing +
CT
Standard
testing
alone Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Acute leukaemia
Carrier 2015 1/423 1/431 57.2 % 1.02 [ 0.06, 16.34 ]
Robin 2016 1/197 0/197 42.8 % 3.02 [ 0.12, 74.47 ]
Subtotal (95% CI) 620 628 100.0 % 1.62 [ 0.20, 13.22 ]
Total events: 2 (Standard testing + CT), 1 (Standard testing alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.45 (P = 0.65)
2 Gynaecological
Carrier 2015 4/423 1/431 61.6 % 4.11 [ 0.46, 36.88 ]
Robin 2016 1/197 1/197 38.4 % 1.00 [ 0.06, 16.10 ]
Subtotal (95% CI) 620 628 100.0 % 2.39 [ 0.43, 13.36 ]
Total events: 5 (Standard testing + CT), 2 (Standard testing alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.62, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
3 Skin: melanoma
Carrier 2015 1/423 1/431 100.0 % 1.02 [ 0.06, 16.34 ]
Subtotal (95% CI) 423 431 100.0 % 1.02 [ 0.06, 16.34 ]
Total events: 1 (Standard testing + CT), 1 (Standard testing alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.01 (P = 0.99)
4 Colorectal
Carrier 2015 1/423 4/431 61.6 % 0.25 [ 0.03, 2.27 ]
Robin 2016 1/197 1/197 38.4 % 1.00 [ 0.06, 16.10 ]
Subtotal (95% CI) 620 628 100.0 % 0.43 [ 0.08, 2.40 ]
Total events: 2 (Standard testing + CT), 5 (Standard testing alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.58, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.96 (P = 0.34)
5 Prostate
Carrier 2015 2/423 1/431 47.2 % 2.04 [ 0.18, 22.61 ]
Robin 2016 3/197 1/197 52.8 % 3.03 [ 0.31, 29.39 ]
0.001 0.01 0.1 1 10 100 1000
Favours standard + CT Favours standard alone
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(. . . Continued)
Study or subgroup
Standard
testing +
CT
Standard
testing
alone Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 620 628 100.0 % 2.52 [ 0.48, 13.12 ]
Total events: 5 (Standard testing + CT), 2 (Standard testing alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.05, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.10 (P = 0.27)
6 Pancreatic
Carrier 2015 3/423 0/431 53.9 % 7.18 [ 0.37, 139.49 ]
Robin 2016 1/197 0/197 46.1 % 3.02 [ 0.12, 74.47 ]
Subtotal (95% CI) 620 628 100.0 % 4.81 [ 0.55, 42.48 ]
Total events: 4 (Standard testing + CT), 0 (Standard testing alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 0.15, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.41 (P = 0.16)
7 Cholangiocarcinoma
Carrier 2015 1/423 2/431 100.0 % 0.51 [ 0.05, 5.63 ]
Subtotal (95% CI) 423 431 100.0 % 0.51 [ 0.05, 5.63 ]
Total events: 1 (Standard testing + CT), 2 (Standard testing alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.55 (P = 0.58)
8 Lymphoma
Carrier 2015 1/423 3/431 64.0 % 0.34 [ 0.04, 3.26 ]
Robin 2016 1/197 0/197 36.0 % 3.02 [ 0.12, 74.47 ]
Subtotal (95% CI) 620 628 100.0 % 0.74 [ 0.09, 5.83 ]
Total events: 2 (Standard testing + CT), 3 (Standard testing alone)
Heterogeneity: Tau2 = 0.39; Chi2 = 1.19, df = 1 (P = 0.27); I2 =16%
Test for overall effect: Z = 0.28 (P = 0.78)
9 Breast
Carrier 2015 0/423 2/431 100.0 % 0.20 [ 0.01, 4.24 ]
Subtotal (95% CI) 423 431 100.0 % 0.20 [ 0.01, 4.24 ]
Total events: 0 (Standard testing + CT), 2 (Standard testing alone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.03 (P = 0.30)
10 Urological
Carrier 2015 0/423 3/431 52.1 % 0.14 [ 0.01, 2.81 ]
Robin 2016 1/197 0/197 47.9 % 3.02 [ 0.12, 74.47 ]
Subtotal (95% CI) 620 628 100.0 % 0.62 [ 0.03, 12.32 ]
Total events: 1 (Standard testing + CT), 3 (Standard testing alone)
Heterogeneity: Tau2 = 2.18; Chi2 = 1.88, df = 1 (P = 0.17); I2 =47%
Test for overall effect: Z = 0.31 (P = 0.75)
11 Liver
Robin 2016 0/197 1/197 100.0 % 0.33 [ 0.01, 8.19 ]
0.001 0.01 0.1 1 10 100 1000
Favours standard + CT Favours standard alone
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Study or subgroup
Standard
testing +
CT
Standard
testing
alone Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 197 197 100.0 % 0.33 [ 0.01, 8.19 ]
Total events: 0 (Standard testing + CT), 1 (Standard testing alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
12 Head and neck
Robin 2016 1/197 0/197 100.0 % 3.02 [ 0.12, 74.47 ]
Subtotal (95% CI) 197 197 100.0 % 3.02 [ 0.12, 74.47 ]
Total events: 1 (Standard testing + CT), 0 (Standard testing alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
13 Lung
Robin 2016 1/197 0/197 100.0 % 3.02 [ 0.12, 74.47 ]
Subtotal (95% CI) 197 197 100.0 % 3.02 [ 0.12, 74.47 ]
Total events: 1 (Standard testing + CT), 0 (Standard testing alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
14 Unknown primary
Carrier 2015 0/423 1/431 100.0 % 0.34 [ 0.01, 8.34 ]
Subtotal (95% CI) 423 431 100.0 % 0.34 [ 0.01, 8.34 ]
Total events: 0 (Standard testing + CT), 1 (Standard testing alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Test for subgroup differences: Chi2 = 8.44, df = 13 (P = 0.81), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours standard + CT Favours standard alone
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Analysis 2.5. Comparison 2 Standard testing plus PET/CT scanning versus standard testing alone, Outcome
5 Characteristics of diagnosed cancer: stage of cancer.
Review: Effect of testing for cancer on cancer- or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE
Comparison: 2 Standard testing plus PET/CT scanning versus standard testing alone
Outcome: 5 Characteristics of diagnosed cancer: stage of cancer
Study or subgroup
Standard
testing +
CT
Standard
testing
alone Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Early
Robin 2016 7/197 4/197 100.0 % 1.78 [ 0.51, 6.17 ]
Subtotal (95% CI) 197 197 100.0 % 1.78 [ 0.51, 6.17 ]
Total events: 7 (Standard testing + CT), 4 (Standard testing alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.37)
2 Advanced
Robin 2016 2/197 2/197 100.0 % 1.00 [ 0.14, 7.17 ]
Subtotal (95% CI) 197 197 100.0 % 1.00 [ 0.14, 7.17 ]
Total events: 2 (Standard testing + CT), 2 (Standard testing alone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 0.23, df = 1 (P = 0.63), I2 =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours standard + CT Favours standard alone
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Analysis 2.6. Comparison 2 Standard testing plus PET/CT scanning versus standard testing alone, Outcome
6 Frequency of an underlying cancer diagnosis.
Review: Effect of testing for cancer on cancer- or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE
Comparison: 2 Standard testing plus PET/CT scanning versus standard testing alone
Outcome: 6 Frequency of an underlying cancer diagnosis
Study or subgroup
Standard
testing +
CT
Standard
testing
alone Odds Ratio Weight Odds Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Carrier 2015 19/423 14/431 71.9 % 1.40 [ 0.69, 2.83 ]
Robin 2016 11/197 4/197 28.1 % 2.85 [ 0.89, 9.12 ]
Total (95% CI) 620 628 100.0 % 1.71 [ 0.91, 3.20 ]
Total events: 30 (Standard testing + CT), 18 (Standard testing alone)
Heterogeneity: Tau2 = 0.01; Chi2 = 1.06, df = 1 (P = 0.30); I2 =5%
Test for overall effect: Z = 1.68 (P = 0.094)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours standard + CT Favours standard alone
A P P E N D I C E S
Appendix 1. Database search strategies
Source Search strategy Hits retrieved
CENTRAL via CRSO #1 MESH DESCRIPTOR Thrombosis 1623
#2 MESH DESCRIPTOR Thromboembolism
1130
#3 MESH DESCRIPTOR Venous Thromboem-
bolism 460
#4MESHDESCRIPTOR Venous Thrombosis EX-
PLODE ALL TREES 2383
#5 (thrombus* or thrombotic* or thrombolic* or
thromboemboli* or thrombos* or embol*):TI,AB,
KY 23592
#6 MESH DESCRIPTOR Pulmonary Embolism
988
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(Continued)
EXPLODE ALL TREES 876
#7 (PE or DVT or VTE):TI,AB,KY 6410
#8 ((vein* or ven*) near thromb*):TI,AB,KY 8228
#9 (blood near3 clot*):TI,AB,KY 4086
#10 (pulmonary near3 clot*):TI,AB,KY 11
#11 (lung near3 clot*):TI,AB,KY 7
#12 #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #
7 OR #8 OR #9 OR #10 OR #11 30819
#13 MESHDESCRIPTORNeoplasms EXPLODE
ALL TREES 66085
#14 malignan*:TI,AB,KY 15050
#15 malignan*:TI,AB,KY 15050
#16 cancer*:TI,AB,KY 109032
#17 (carcinoma* or adenocarcinoma*):TI,AB,KY
34396
#18 tumour* or tumor* 53285
#19 Trousseau 116
#20 #13 OR #14 OR #15 OR #16 OR #17 OR #
18 OR #19 159584
#21 MESH DESCRIPTOR Mass Screening EX-
PLODE ALL TREES 3452
#22 MESH DESCRIPTOR Early Diagnosis EX-
PLODE ALL TREES 1383
#23 screen*:TI,AB,KY 37148
#24 diagnos*:TI,AB,KY 155907
#25 assess*:TI,AB,KY 345626
#26 investigat*:TI,AB,KY 191309
#27 test:TI,AB,KY 164229
#28 testing:TI,AB,KY 36477
#29 #21 OR #22 OR #23 OR #24 OR #25 OR #
26 OR #27 OR #28 627438
#30 #12 AND #20 AND #29 3087
#31 01/01/2017 TO 11/07/2018:CD 297578
#32 #30 AND #31 988
Clinicaltrials.gov screening and thrombosis | Neoplasms | Start date
on or after 01/01/2017 | Last update posted on or
before 07/11/2018
2
ICTRP Search Portal screen* and thromb* AND (cancer OR neoplas*) 0
MEDLINE 1 THROMBOSIS/ 65754
2 THROMBOEMBOLISM/ 22598
3 Venous Thromboembolism/ 8353
4 exp Venous Thrombosis/ 51491
5 (thrombus* or thrombotic* or thrombolic* or
thromboemboli* or thrombos* or embol*).ti,ab.
300204
6 exp Pulmonary Embolism/ 36266
549
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7 (PE or DVT or VTE).ti,ab. 47179
8 ((vein* or ven*) adj thromb*).ti,ab. 61230
9 (blood adj3 clot*).ti,ab. 10069
10 (pulmonary adj3 clot*).ti,ab. 189
11 (lung adj3 clot*).ti,ab. 48
12 or/1-11 388932
13 exp NEOPLASMS/ 3057674
14 malignan*.ti,ab. 512186
15 neoplas*.ti,ab. 240131
16 cancer*.ti,ab. 1517621
17 (carcinoma* or adenocarcinoma*).ti,ab. 677364
18 (tumour* or tumor*).ti,ab. 1502982
19 Trousseau.ti,ab. 313
20 or/13-19 3885141
21 exp Mass Screening/ 116649
22 exp Early Diagnosis/ 40905
23 screen*.ti,ab. 641466
24 diagnos*.ti,ab. 2165172
25 assess*.ti,ab. 2516167
26 investigat*.ti,ab. 3065445
27 test.ti,ab. 1289871
28 testing.ti,ab. 471233
29 or/21-28 7959109
30 12 and 20 and 29 25950
31 randomized controlled trial.pt. 463720
32 controlled clinical trial.pt. 92491
33 randomized.ab. 415764
34 placebo.ab. 190130
35 drug therapy.fs. 2028849
36 randomly.ab. 293491
37 trial.ab. 432571
38 groups.ab. 1811637
39 or/31-37 2880739
40 exp animals/ not humans.sh. 4472147
41 39 not 40 2578287
42 30 and 41 5263
43 (2017* or 2018*).ed. 1443224
44 42 and 43 549
45 from 44 keep 1-549 549
Embase 1 thrombosis/ 124873
2 thromboembolism/ 64224
3 venous thromboembolism/ 31164
4 exp vein thrombosis/ 118502
5 (thrombus* or thrombotic* or thrombolic* or
thromboemboli* or thrombos* or embol*).ti,ab.
432307
6 exp lung embolism/ 84483
7 (PE or DVT or VTE).ti,ab. 75463
3042
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8 ((vein* or ven*) adj thromb*).ti,ab. 91606
9 (blood adj3 clot*).ti,ab. 13282
10 (pulmonary adj3 clot*).ti,ab. 289
11 (lung adj3 clot*).ti,ab. 75
12 or/1-11 615807
13 exp neoplasm/ 4123701
14 malignan*.ti,ab. 709885
15 neoplas*.ti,ab. 315603
16 cancer*.ti,ab. 2121608
17 (carcinoma* or adenocarcinoma*).ti,ab. 902868
18 (tumour* or tumor*).ti,ab. 2002209
19 Trousseau.ti,ab. 492
20 or/13-19 5009281
21 12 and 20 121984
22 exp mass screening/ 214485
23 exp early diagnosis/ 94736
24 screen*.ti,ab. 885407
25 diagnos*.ti,ab. 3075877
26 assess*.ti,ab. 3532058
27 investigat*.ti,ab. 3881465
28 test.ti,ab. 1807591
29 testing.ti,ab. 653679
30 or/22-29 10515417
31 21 and 30 59125
32 randomized controlled trial/ 509418
33 controlled clinical trial/ 460076
34 random$.ti,ab. 1318239
35 randomization/ 78687
36 intermethod comparison/ 236961
37 placebo.ti,ab. 274806
38 (compare or compared or comparison).ti. 471921
39 ((evaluated or evaluate or evaluating or assessed
or assess) and (compare or compared or comparing
or comparison)).ab. 1766840
40 (open adj label).ti,ab. 64885
41 ((double or single or doubly or singly) adj (blind
or blinded or blindly)).ti,ab. 210042
42 double blind procedure/ 151638
43 parallel group$1.ti,ab. 21941
44 (crossover or cross over).ti,ab. 93462
45 ((assign$ or match or matched or allocation) adj5
(alternate or group$1 or intervention$1 or patient$1
or subject$1 or participant$1)).ti,ab. 284838
46 (controlled adj7 (study or design or trial)).ti,ab.
296995
47 (volunteer or volunteers).ti,ab. 225436
48 trial.ti. 252721
49 or/32-48 3971781
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50 31 and 49 14132
51 (2017* or 2018*).em. 3704407
52 50 and 51 3042
53 from 52 keep 3001-3042 42
CINAHL S45 S43 AND S44 64
S44 EM 2017 OR EM 2018 375,192
S43 S29 AND S42 1,031
S42 S30 OR S31 OR S32 OR S33 OR S34 OR S35
OR S36 OR S37 OR S38 OR S39 OR S40 OR S41
342,779
S41 MH “Random Assignment” 38,773
S40 MH “Single-Blind Studies” or MH “Double-
Blind Studies” or MH “Triple-Blind Studies” 32,756
S39 MH “Crossover Design” 11,217
S38 MH “Factorial Design” 920
S37 MH “Placebos” 8,357
S36 MH “Clinical Trials” 93,009
S35 TX “multi-centre study” OR “multi-center
study” OR “multicentre study” OR “multicenter
study” OR “multi-site study” 4,493
S34 TX crossover OR “cross-over” 14,582
S33 AB placebo* 28,376
S32 TX random* 219,464
S31 TX trial* 250,950
S30 TX “latin square” 142
S29 S12 AND S20 AND S28 4,143
S28 S21 OR S22 OR S23 OR S24 OR S25 OR S26
OR S27 1,385,201
S27 TX testing 80,806
S26 TX test 534,812
S25 TX investigat* 247,601
S24 TX assess* 571,672
S23 TX diagnos* 564,639
S22 TX screen* 112,837
S21 (MH “Early Diagnosis+”) 5,934
S20 S13 OR S14 OR S15 OR S16 OR S17 OR S18
OR S19 360,362
S19 TX Trousseau 334
S18 TX tumour* or tumor* 67,488
S17 TX carcinoma* or adenocarcinoma* 38,313
S16 TX cancer* 244,456
S15 TX neoplas* 211,854
S14 TX malignan* 25,785
S13 (MH “Neoplasms+”) 245,346
S12 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7
OR S8 OR S9 OR S10 OR S11 44,954
S11 TX lung n3 clot* 22
64
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S10 TX pulmonary n3 clot* 29
S9 TX blood n3 clot* 913
S8 TX (vein* or ven*) N thromb* 121
S7 TX PE or DVT or VTE 11,031
S6 (MH “Pulmonary Embolism”) 4,771
S5 TX thrombus* or thrombotic* or thrombolic* or
thromboemboli* or thrombos* or embol* 36,269
S4 (MH “Venous Thrombosis+”) 6,363
S3 (MH “Venous Thromboembolism”) 3,091
S2 (MH “Thromboembolism”) 3,239
S1 (MH “Thrombosis”) 4,638
AMED 1 thrombosis/ 199
2 thromboembolism/ 72
3 (thrombus* or thrombotic* or thrombolic* or
thromboemboli* or thrombos* or embol*).ti,ab. 640
4 (PE or DVT or VTE).ti,ab. 245
5 ((vein* or ven*) adj thromb*).ti,ab. 310
6 (blood adj3 clot*).ti,ab. 34
7 (pulmonary adj3 clot*).ti,ab. 0
8 (lung adj3 clot*).ti,ab. 0
9 or/1-8 866
10 exp Neoplasms/ 14356
11 malignan*.ti,ab. 1398
12 neoplas*.ti,ab. 359
13 cancer*.ti,ab. 12116
14 (carcinoma* or adenocarcinoma*).ti,ab. 1443
15 (tumour* or tumor*).ti,ab. 3725
16 or/10-15 19252
17 9 and 16 119
18 exp Mass screening/ 642
19 screen*.ti,ab. 4769
20 diagnos*.ti,ab. 15264
21 assess*.ti,ab. 38696
22 investigat*.ti,ab. 26974
23 test.ti,ab. 18151
24 testing.ti,ab. 6475
25 or/18-24 82460
26 17 and 25 45
27 exp CLINICAL TRIALS/ 3749
28 RANDOM ALLOCATION/ 314
29 DOUBLE BLIND METHOD/ 657
30 Clinical trial.pt. 1211
31 (clinic* adj trial*).tw. 5381
32 ((singl* or doubl* or trebl* or tripl*) adj (blind*
or mask*)).tw. 2833
33 PLACEBOS/ 586
34 placebo*.tw. 3102
35 random*.tw. 17520
0
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36 PROSPECTIVE STUDIES/ 1097
37 or/27-36 22515
38 26 and 37 3
39 (“2017” or “2018”).yr. 2075
40 38 and 39 0
Appendix 2. Extensive tests versus tests at the physician’s discretion
Extensive tests versus tests at the physician’s discretion
Patient or population: people with unprovoked VTE
Setting: hospital
Intervention: extensive tests
Comparison: tests at physician’s discretion
Outcomes Anticipated absolute effects* (95%
CI)
Relative effect
(95% CI)
No of partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Risk with tests
at physician’s
discretion
Riskwith exten-
sive tests
Char-
acteristics of di-
agnosed cancer:
type of cancer -
lung
Study population OR 2.08
(0.19 to 23.34)
201
(1 RCT)
⊕⊕©©
Low1
-
10 per 1000 20 per 1000
(2 to 188)
Char-
acteristics of di-
agnosed cancer:
type of cancer -
bladder
Study population OR 2.08
(0.19 to 23.34)
201
(1 RCT)
⊕⊕©©
Low1
-
10 per 1000 20 per 1000
(2 to 188)
Char-
acteristics of di-
agnosed cancer:
type of cancer -
stomach
Study population OR 1.03
(0.06 to 16.71)
201
(1 RCT)
⊕⊕©©
Low1
-
10 per 1000 10 per 1000
(1 to 142)
Char-
acteristics of di-
agnosed cancer:
type of cancer -
kidney
Study population OR 3.12
(0.13 to 77.55)
201
(1 RCT)
⊕⊕©©
Low1
-
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0 per 1000 0 per 1000
(0 to 0)
Char-
acteristics of di-
agnosed cancer:
type of cancer -
adrenal gland
Study population OR 3.12
(0.13 to 77.55)
201
(1 RCT)
⊕⊕©©
Low1
-
0 per 1000 0 per 1000
(0 to 0)
Char-
acteristics of di-
agnosed cancer:
type of cancer -
liver
Study population OR 3.12
(0.13 to 77.55)
201
(1 RCT)
⊕⊕©©
Low1
-
0 per 1000 0 per 1000
(0 to 0)
Char-
acteristics of di-
agnosed cancer:
type of cancer -
uterus
Study population OR 3.12
(0.13 to 77.55)
201
(1 RCT)
⊕⊕©©
Low1
-
0 per 1000 0 per 1000
(0 to 0)
Char-
acteristics of di-
agnosed cancer:
type of cancer -
breast
Study population OR 1.03
(0.06 to 16.71)
201
(1 RCT)
⊕⊕©©
Low1
-
10 per 1000 10 per 1000
(1 to 142)
Char-
acteristics of di-
agnosed cancer:
type of cancer -
ovary
Study population OR 3.12
(0.13 to 77.55)
201
(1 RCT)
⊕⊕©©
Low1
-
0 per 1000 0 per 1000
(0 to 0)
Char-
acteristics of di-
agnosed cancer:
type of cancer -
colon
Study population OR 0.51
(0.05 to 5.72)
201
(1 RCT)
⊕⊕©©
Low1
-
20 per 1000 10 per 1000
(1 to 103)
Char-
acteristics of di-
agnosed cancer:
type of cancer -
prostate
Study population OR 0.51
(0.05 to 5.72)
201
(1 RCT)
⊕⊕©©
Low1
-
20 per 1000 10 per 1000
(1 to 103)
Char-
acteristics of di-
agnosed cancer:
type of cancer -
Study population OR 0.20
(0.01 to 4.26)
201
(1 RCT)
⊕⊕©©
Low1
-
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pancreas
20 per 1000 4 per 1000
(0 to 79)
*The risk in the intervention group (and its 95% conﬁdence interval) is based on the assumed risk in the comparison group and
the relative effect of the intervention (and its 95% CI).
CI: conﬁdence interval; OR: odds ratio; RCT: randomised controlled trial; VTE: venous thromboembolism.
GRADE Working Group grades of evidence
High quality: We are very conﬁdent that the true effect lies close to that of the estimate of the effect.
Moderate quality:We are moderately conﬁdent in the effect estimate: The true effect is likely to be close to the estimate of the effect,
but there is a possibility that it is substantially different.
Low quality:Our conﬁdence in the effect estimate is limited: The true effect may be substantially different from the estimate of the
effect.
Very low quality: We have very little conﬁdence in the effect estimate: The true effect is likely to be substantially different from the
estimate of effect
1 Quality of evidence downgraded for imprecision due to low number of events. Downgraded further as risk of bias high in study
by Piccioli 2004b. Study terminated early after inclusion of only 201 participants after 5 years for several reasons. First, only ﬁve of
more than 40 potential participating centres could contribute participants to study. Second, some medical ethics committees rejected
the protocol because of absence of screening for occult cancer in the control group, other centres could not start because the proposed
extensive screening was judged unethical. Finally, identiﬁcation of cancer at an apparent early stage in extensive screening group led to
an increasing tendency among physicians in participating hospitals to initiate screening for cancer in control participants.
Appendix 3. Standard testing plus PET/CT scanning versus standard testing alone
Standard testing plus PET/CT scanning versus standard testing alone
Patient or population: people with unprovoked VTE
Setting: hospital
Intervention: standard testing + PET/CT scanning
Comparison: standard testing alone
Outcomes Anticipated absolute effects* (95%
CI)
Relative effect
(95% CI)
No of partici-
pants
(studies)
Quality of the
evidence
(GRADE)
Comments
Risk with
standard testing
alone
Risk with stan-
dard testing +
PET/CT scan-
ning
Char-
acteristics of di-
agnosed cancer:
Study population OR 1.62
(0.20 to 13.22)
1248
(2 RCTs)
⊕⊕©©
Low 1,2
-
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type of cancer -
acute leukaemia
2 per 1000 3 per 1000
(0 to 21)
Char-
acteristics of di-
agnosed cancer:
type of cancer -
gynaecological
Study population OR 2.39
(0.43 to 13.36)
1248
(2 RCTs)
⊕⊕©©
Low 1,2
-
3 per 1000 8 per 1000
(1 to 41)
Char-
acteristics of di-
agnosed cancer:
type of cancer -
skin: melanoma
Study population OR 1.02
(0.06 to 16.34)
854
(1 RCT)
⊕⊕⊕©
Moderate 2
-
2 per 1000 2 per 1000
(0 to 37)
Char-
acteristics of di-
agnosed cancer:
type of cancer -
colorectal
Study population OR 0.43
(0.08 to 2.40)
1248
(2 RCTs)
⊕⊕©©
Low 1,2
-
8 per 1000 3 per 1000
(1 to 19)
Char-
acteristics of di-
agnosed cancer:
type of cancer -
prostate
Study population OR 2.52
(0.48 to 13.12)
1248
(2 RCTs)
⊕⊕©©
Low 1,2
-
3 per 1000 8 per 1000
(2 to 40)
Char-
acteristics of di-
agnosed cancer:
type of cancer -
pancreatic
Study population OR 4.81
(0.55 to 42.48)
1248
(2 RCTs)
⊕⊕©©
Low 1,2
-
0 per 1000 0 per 1000
(0 to 0)
Char-
acteristics of di-
agnosed cancer:
type of cancer
- cholangiocar-
cinoma
Study population OR 0.51
(0.05 to 5.63)
854
(1 RCT)
⊕⊕⊕©
Moderate 2
-
5 per 1000 2 per 1000
(0 to 26)
Char-
acteristics of di-
agnosed cancer:
type of cancer -
lymphoma
Study population OR 0.74
(0.09 to 5.83)
1248
(2 RCTs)
⊕⊕©©
Low 1,2
-
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5 per 1000 4 per 1000
(0 to 27)
Char-
acteristics of di-
agnosed cancer:
type of cancer -
breast
Study population OR 0.20
(0.01 to 4.24)
854
(1 RCT)
⊕⊕⊕©
Moderate 2
-
5 per 1000 1 per 1000
(0 to 19)
Char-
acteristics of di-
agnosed cancer:
type of cancer -
urological
Study population OR 0.62
(0.03 to 12.32)
1248
(2 RCTs)
⊕⊕©©
Low 1,2
-
5 per 1000 3 per 1000
(0 to 56)
Char-
acteristics of di-
agnosed cancer:
type of cancer -
liver
Study population OR 0.33
(0.01 to 8.19)
394
(1 RCT)
⊕⊕©©
Low 1,2
-
5 per 1000 2 per 1000
(0 to 40)
Char-
acteristics of di-
agnosed cancer:
type of cancer -
head and neck
Study population OR 3.02
(0.12 to 74.47)
394
(1 RCT)
⊕⊕©©
Low 1,2
-
0 per 1000 0 per 1000
(0 to 0)
Char-
acteristics of di-
agnosed cancer:
type of cancer -
lung
Study population OR 3.02
(0.12 to 74.47)
394
(1 RCT)
⊕⊕©©
Low 1,2
-
0 per 1000 0 per 1000
(0 to 0)
Char-
acteristics of di-
agnosed cancer:
type of cancer
- unknown pri-
mary
Study population OR0.34 (0.01 to
8.34)
854
(1 RCT)
⊕⊕⊕©
Moderate 2
-
5 per 1000 8 per 1000
(1 to 41)
*The risk in the intervention group (and its 95% conﬁdence interval) is based on the assumed risk in the comparison group and
the relative effect of the intervention (and its 95% CI).
CI: conﬁdence interval;OR:odds ratio;PET/CT:positron emission tomography/computed tomography;RCT: randomised controlled
trial; VTE: venous thromboembolism.
GRADE Working Group grades of evidence
High quality: We are very conﬁdent that the true effect lies close to that of the estimate of the effect.
Moderate quality:We are moderately conﬁdent in the effect estimate: The true effect is likely to be close to the estimate of the effect,
but there is a possibility that it is substantially different.
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Low quality:Our conﬁdence in the effect estimate is limited: The true effect may be substantially different from the estimate of the
effect.
Very low quality: We have very little conﬁdence in the effect estimate: The true effect is likely to be substantially different from the
estimate of effect
1 Quality of evidence downgraded as risk of detection bias high for one study as outcome assessors not blinded to treatment (Robin
2016).
2 Quality of evidence downgraded for imprecision due to low number of events.
WH A T ’ S N E W
Date Event Description
11 July 2018 New citation required but conclusions have not changed Search updated.Nonew studies included or excluded. Ad-
ditional references to previously included studies added.
No change to conclusions
11 July 2018 New search has been performed Search updated. No new studies included or excluded.
H I S T O R Y
Protocol ﬁrst published: Issue 11, 2013
Review ﬁrst published: Issue 2, 2015
Date Event Description
6 November 2017 Amended Error in assumed control risk for outcome cancer-re-
lated mortality in Summary of ﬁndings table ’Exten-
sive tests versus tests at the physician’s discretion’ cor-
rected and inconsistencies between quality of evidence
reported in text and Summary of ﬁndings table cor-
rected
20 July 2017 New search has been performed Searches rerun, two new included studies added
20 July 2017 New citation required but conclusions have not
changed
Searches rerun, two new included studies added, Sum-
mary of Findings table added. No change to conclu-
sions
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The primary outcome ’Non-cancer-related mortality (death due to some cause other than cancer or cancer-related treatment)’ was re-
phrased to ’all-cause mortality’ for clarity.
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